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Abstract: Phenols are a wide family of phytochemicals that are characterized by large chemical
diversity and are considered to bioactive molecules of foods, beverages, and botanicals. Although
they have a multitude of biological actions, their beneficial effects are rarely evidenced in clinical
research with high scientific rigor. This may occur due to the presence of numerous confounders, such
as the modulation of phenol bioavailability, which can be regulated by microbiota, age, sex-gender.
Sex-gender is an important determinant of health and well-being, and has an impact on environmental
and occupational risks, access to health care, disease prevalence, and treatment outcomes. In addition,
xenobiotic responses may be strongly influenced by sex-gender. This review describes how sex–gender
differentially influences the activities of phenols also in some critical periods of women life such as
pregnancy and lactation, considering also the sex of fetuses and infants. Thus, sex–gender is a variable
that must be carefully considered and should be used to propose directions for future research on the
road to tailored medicine and nutrition.
Keywords: sex–gender; phenols; pharmacokinetics; microbiota; pregnancy; lactation; developmental
trajectory
1. Introduction
A total of 52 million US citizens use complementary and alternative medicines [1]. Natural
compounds are also largely consumed in Asia, Europe, and Latin America (30–40% of the population) [2].
Among them, the use of botanicals continues to increase globally [3]. About 20,000 different botanical
formulations are available in the USA market [4] and many of them are widely used in complementary
and alternative medicines [5]. The use of botanicals depends on age, education, whether the individual
is physically active, and sex [[6] and cited literature].
Rigorous findings regarding the efficacy and safety profile of botanicals are lacking ([6] and
cited literature). There are some biases in the research focusing on the health effects of botanicals
including phenols, such as their high placebo effect, which often leads to equivocal and non-significant
effects ([6] and cited literature). The botanical response is also influenced by individual factors (age,
sex-gender, body size and composition, genetics, psychological stressors (loneliness, etc.), social status,
instruction, microbiota, lifestyles, etc.). The botanicals activity and the outcomes of preclinical and
clinical investigations may be dependent on the above factors.
Here, we focus on phenols, secondary metabolites of plants, and sex and gender in consideration
of the fact that women are the biggest users of botanicals ([6] and cited literature).
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There are different definitions of sex and gender [7–10]. According to the World Health Organization,
the terms “gender” or “sex” refer to two different concepts. Sex “refers to the set of biological characteristics
that define humans as female or male”; whereas gender “refers to the socially constructed roles, behaviors,
activities, and attributes that a given society considers appropriate for men and women”. Evidently, it is
easier to study sexual dimorphism, because sex is considered as a dichotomous variable; while gender is
a much more complex because it implicates socio-cultural and political constructions. Sex and gender
influence each other through complex and continue interactions; thus, sometimes it is impossible to
distinguish between the two concepts and, therefore, we, as others have [11,12], prefer to use the mixed
term, sex–gender.
Recently, the biological activities of phenols are reviewed [13–18], but often, the sex–gender
aspect is not appropriately studied, with some exceptions [6,19,20]. Indeed, despite a large amount
of information regarding the biological activity of phenols, clear evidence regarding their effect on
human health is lacking [13–16]. Beyond individual factors, their response is largely dependent on
their chemical structure, pharmacokinetic properties of the single phenol. Here, we focus on critical
periods of a woman’s life, namely gestation and lactation, considering the influences of sex of the
fetus. In addition, starting from “Thrifty Phenotype Hypothesis” [21], the early and tardive effects of
sex–gender of the fetus on phenol exposure in pregnancy and lactation are discussed.
2. Plant Materials
Botanicals are often complex mixtures and can present a great variability [22] depending on cultivar,
the country of cultivation or spontaneous growth (altitudes, climates), the season of harvest [23,24],
and practices of manufacturers [25]. Thus, it is not surprising that Simpraga et al. [26] defined the
plants as “chemical factories”, because they generate numerous compounds. Primary metabolites
play a role in basal functions, whereas secondary ones are involved in the defense against numerous
stressors [22,27].
Plants produce a large number of phenols (>8000), but edible plants produce only several
hundred of phenols [28]. Chemically, phenols are classified and categorized as flavonoids (isoflavones,
flavones, flavanols (catechins and proanthocyanidins), flavanones, anthocyanidins and flavonols, and
non-flavonoid compounds (phenolic acids, stilbenes, lignans). Flavonoids have two aromatic rings
linked through a three-carbon chain (Figure 1). Tannins are oligomers and polymers of flavonoids and
are classified into two groups, condensed tannins and hydrolyzable tannins.
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amounts of isoflavones and lignans are present in soy bean and in flax seed, respectively [29]. In olive 
fruit and in virgin olive oil are present numerous phenols among them 5-hydroxytyrosol (HT) and 
oleuropein derivatives are noteworthy [30]. Notably, humans may produce tyrosol (Tyr) and HT as 
minor metabolites in dopamine and tyramine metabolism [31]. In plants, phenols are mainly 
presented as glycosides ([6] and cited literature). 
3. Sex Differences in Plants 
Plants are complex entities that, in part, depend on natural selection and evolution [22]. While 
the stress responses of plants have been widely investigated [32], studies on the influences of sex on 
stress response are scarcer. Recently, it has been shown that the sex of a plant may influence phenol 
production. Leaves collected from Pistacia atlantica vary with regard to their contents of total phenols, 
flavonoids, and condensed tannins depending on the month they were harvested, their growing 
region, and sex, whereas their antioxidant properties are not influenced by the sex of plant [33]. In 
Salix myrsinifolia, the amount of phenols is enhanced by prolonged exhibition to UV and this 
enhancement depends on the sex of the plant. In particular, UV radiation reduces the activities of 
phenol oxidase, especially in male plants, whereas guaiacol peroxidase activity is not affected by UV 
radiation and sex [34]. Male Populus cathayana Rehd are more protected from UV than females. 
Accordingly, males possess a greater antioxidant capacity and higher anthocyanin levels than 
females [35]. Whereas in Ginkgo biloba and Rhodiola rosea L., the phenolic amount and the defense 
versus oxidant do not diverge in male and female [36,37]. 
This point requires further investigation because it could be a criterion in choosing the sex of the 
plant in order to use the right sex to obtain more phenols. 
4. Pharmacokinetics of Phenols: Influence of Sex–Gender 
Bioavailability is an essential aspect when investigating the phenols’ effects in vivo. Only 1–10% 
of the phenol assumption can be detected in plasma and urine, where phenol contents range from 
nM to low µM [16]. Anthocyanidins and flavones have a low bioavailability, followed by flavanols, 
flavanones, and soy isoflavones. Glycosides and aglycones have different levels of bioavailability. 
However, glycosides may be metabolized in the gut, contributing to the high variability in phenol 
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High amounts of coumestans and stilbenes are measured in clover and in cocoa- and
grape-containing products, respectively [29]. High amounts of isoflavones (genistin, daidzin, and
glycitin) and lignans are present in soybean and in flax seed, respectively [29]. Formononetin and
biochanin A are present in the red clover and are precursors of genistein and daidzein, respectively [6].
High amounts of isoflavones and lignans are present in soy bean and in flax seed, respectively [29].
In olive fruit and in virgin olive oil are present numerous phenols among them 5-hydroxytyrosol (HT)
and oleuropein derivatives are noteworthy [30]. Notably, humans may produce tyrosol (Tyr) and
HT as minor metabolites in dopamine and tyramine metabolism [31]. In plants, phenols are mainly
presented as glycosides ([6] and cited literature).
3. Sex Differences in Plants
Plants are complex entities that, in part, depend on natural selection and evolution [22]. While
the stress responses of plants have been widely investigated [32], studies on the influences of sex on
stress response are scarcer. Recently, it has been shown that the sex of a plant may influence phenol
production. Leaves collected from Pistacia atlantica vary with regard to their contents of total phenols,
flavonoids, and condensed tannins depending on the month they were harvested, their growing region,
and sex, whereas their antioxidant properties are not influenced by the sex of plant [33]. In Salix
myrsinifolia, the amount of phenols is enhanced by prolonged exhibition to UV and this enhancement
depends on the sex of the plant. In particular, UV radiation reduces the activities of phenol oxidase,
especially in male plants, whereas guaiacol peroxidase activity is not affected by UV radiation and
sex [34]. Male Populus cathayana Rehd are more protected from UV than females. Accordingly, males
possess a greater antioxidant capacity and higher anthocyanin levels than females [35]. Whereas in
Ginkgo biloba and Rhodiola rosea L., the phenolic amount and the defense versus oxidant do not diverge
in male and female [36,37].
This point requires further investigation because it could be a criterion in choosing the sex of the
plant in order to use the right sex to obtain more phenols.
4. Pharmacokinetics of Phenols: Influence of Sex–Gender
Bioavailability is an essential aspect when investigating the phenols’ effects in vivo. Only 1–10%
of the phenol assumption can be detected in plasma and urine, where phenol contents range from
nM to low µM [16]. Anthocyanidins and flavones have a low bioavailability, followed by flavanols,
flavanones, and soy isoflavones. Glycosides and aglycones have different levels of bioavailability.
However, glycosides may be metabolized in the gut, contributing to the high variability in phenol
bioavailability because the combined activity of different enzymes of the host and of microbiota and
the different transporters [38].
There are data supporting the importance of ethnicity in the bioavailability of phenols. Circulating
daidzein, genistein, and equol are higher in Japanese men and women (>40 years old) versus British
men and women. In addition, more Japanese men and women are able to produce equol versus English
men and women. Finally, enterolactone has the same serum concentration in Japanese and English
cohorts [39].
Importantly, the sexual dimorphisms that can affect the phenol kinetics are reported in Table 1.
4.1. Absorption
The oral bioavailability of exogenous compounds depends on the characteristics of individuals
(stomach pH, gastrointestinal mobility, enzymatic degradations, mucus secretion, transporters,
microbiota, age, etc.) and these often present a marked sexual dimorphism (Tables 1 and 2) and by the
chemical structure of the molecule, plant matrix, and the formulations.
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Table 1. Some sex–gender differences involved in pharmacokinetics.
Parameters Male/Female
Fat +F (human)
Muscular mass +M (human)
Body weight +M (human)
Height +M (human)
Heart rate −M (human)
Regional blood flow +M (human)
Plasma volume +F (human)
Total water +M (human)
Gastric pH [acidity] +M (human)
Gastric emptying +M (human)
Gastro-intestinal mobility +M (human)
Glomerular filtration rate +M (human)
CYP1A2 +M (human)
CYP2A6 +F (human)
CYP2A7 +F (rat)
CYP2E1 +M (human)
CYP3A4 +F (human)
CYP3A only in males (pig)
CYP3A5 +M (human)
CYP3A7 +F (human)
CYP3A9 +F (human)
CYP2B6 +M (human)
CYP2C9 = (human)
CYP2C19 = (human)
CYP2D6 +M (human)
CYP7A1 +F (human)
COMT +M (human)
GST +M (rat)
GSTA1/A2 +F (human)
UDP-glucuronosyl-transferases
+M [UGT1A6 (pig); UGT2b1 (liver); UGT2b5/37/38 (kidney);
UGT1a6 (lung); UGT2b15; UGT2b17]
+F [UGT 1a1 (human); UGT 1a5 (liver); UGT 1a2 (kidney); UGT
2b35 (brain)]
SULT1A1 +F than men with high androgen levels (human)
SULT1E1 liver only in males (rat)
Oatp1 = (rat)
Oatp2 = (rat)
Oatp4 +F
= (rat)
P-glycoprotein +M (human)
Liver SLC3A1 +F (human)
Liver SLC13A1 +M (human)
Liver SLC10A1 +F (human)
Liver ACSL4 +F (human)
Data are obtained from ([40–42] and cited literature) F = female, M = male; Oatp = Organic-anion-transporting
polypeptide, SLC = solute carrier family
Generally, the human stomach is of low importance for absorption. Indeed, black raspberry
anthocyanins are one of the few compounds that can be absorbed in the stomach [43].
The most important location for absorption is the intestine. The absorption mainly occurs by
passive diffusion, although some phenols may be transported by the sodium-glucose co-transporter 1,
which at renal level diverges between male and female rats ([19] and cited literature). The absorption
also depends on sugar, because it modulates the hydrolysis of glycosides by lactase phlorizin hydrolase
and by gut micro-organisms, which produce by β-glucosidases ([19,44] and cited literature).
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Phenol absorption may also be regulated by several transmembrane proteins, such as P-glycoprotein
(P-gp), breast cancer resistant protein (BCRP), peptide transporter (PEPT), and organic anion transporting
polypeptide (Oatp) [45]. BCRP excretes phenol metabolites into the gut, thus decreasing the bioavailability
of phenols participating in their recycling [46]. This is of special value for glucuronide and sulfate
conjugates, which are more hydrophilic than their precursor and, therefore, the efflux transporter is
vital to facilitate their exit from the cells [46]. Notably, BCRP is more expressed in the liver of male
rats and men versus the liver of female rats and women [47]. Genistein, daidzein, and many of their
sulfated conjugates are transported by BCRP; with genistein being more absorbed in female rats versus
male rats [48]. Finally, others show that the bioavailability of genistein and of its aglycone is much
higher in female compared to male rats and the authors suggest that it depends on the recycling
process [49]. Recently, it has been shown that isoflavones are inhibitors of these transporters [48].
Considering the sex differences present at gastrointestinal level (Table 1), it is plausible that sex
differences are present in phenols gastrointestinal absorption.
4.2. Metabolism
The phenol biotransformation begins in the mouth (Figure 2), where the phenols interact with
saliva salivary glands secretions, epithelial cells, micro-organisms, and both cell types produce
β-glycosidases ([19] and cited literature). However, the real value of the oral transformations is unclear
due to the short time that most foods and/or supplements remain in the mouth. However, aglycones of
black raspberry anthocyanins could be detected in the mouth, and the saliva contains glucuronidated
anthocyanin conjugates [43]. Importantly, oral phenol metabolism may be influenced by female sexual
hormones, suggesting that mouth microbiota in women may vary with fertile status [50]. In addition,
hormone replacement therapy may change oral microbiota but these are not univocal data ([50] and
cited literature). Importantly, oral microbiota seems to change during pregnancy [51] and this could
have some consequences on phenol metabolism.
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Figure 2. Schematic predicted routes for absorption and elimination of dietary phenols.
The bulk of phenols are metabolized in the intestine where they are hydrolyzed by lactase
phlorizin hydrolase and by β-glucosidases of gut microbiota [52]. Unlike humans, rats and mice
of both sexes produce equol similarly [53], indicating that phenol metabolism is species-specific.
Additionally, the cytochrome P450 (CYP) enzymes, uridine diphospho-glucuronosyltransferase
(UGT), sulfotransferase (SULT), N-acetyltransferase (NAT) and glutathione S-transferase (GST) and
catechol-O-methyl transferase (COMT) are involved in phenols metabolism (Figure 2) [54].
Relevantly, CYP present numerous sexual dimorphisms (Table 1). CYP activities is under the control
of constitutive androstane receptor (CAR), pregnane X receptor (PXR), peroxisome proliferator-activated
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receptor α (PPARα), and aryl hydrocarbon receptor (AhR) [19]. CAR regulates genes of CYP2B6,
CYP2C8/9, and CYP3A4, UGT, and some carriers such as multidrug resistance-associated proteins 2 and
3 ([55] and cited literature). In women, CYP2B6 activity is higher compared to men, although there are no
univocal data [56,57]. CYP2B6 is more elevated in Hispanic women versus white or African–American
women [19]. In addition, CYP2B6 shows a sex difference in its genetic polymorphisms, with 1459C > T
SNP and intron-3 15582C > T SNP associated with a very low level of CYP2B6 in females [41]. CAR
regulates the dimorphic induction of the CYP2B1 gene (which is lower in female than in male rat
livers). Interestingly, sexual male hormones appear to inhibit CAR [19], whereas estrogens activate
it [58]. Furthermore, the activity of CAR is influenced by pregnancy [59].
PXR regulates numerous CYP (CYP3A, CYP2B, CYP2C, CYP2A6), and several other enzymes
(UGT1A1, UGT1A9, UGT1A3, UGT1A4, UGT1A6, GST, SULT) and some organic anion transporters [60].
A rich-fat diet reduces protein expression of estrogen receptor α (ERα) in hepatic and white adipose
tissue in transgenic female mice expressing the human PXR gene [61]. Phenols may regulate the activity
of PXR ([19] and cited literature). Importantly, PXR plays a role in the variation of CYP enzymes
observed in pregnancy [62].
PPARα activates both numerous CYP such as CYP2C8, CYP3A4, CYP7A1, CYP8B1, and other
enzymes such as GST and UGT1A9 [63]. Importantly, CYP3A4 is also induced via PXR and CAR [64].
The expression of PPARα is higher in the male liver and in the activated male T cells compared to in
female ones [65,66]. After fasting, PPARα protein and mRNA are more expressed in the hepatic tissue
of male rats versus female rats. In detail, PPARα mRNA increases by 72% and 52% in males and in
females, respectively [66]. This sexual dimorphism is not evident after hypophysectomy. Furthermore,
in lymphocytes, PPARα mRNA and protein are more marked in male mice versus female ones [67];
however, T cells function and immune virulence are altered by PPARα only in males [67].
AhR activity depends on species, strain, sex, age, tissue, and cell-specific responses. It is activated
by quercetin and resveratrol and its derivates in primary human hepatocytes [68,69]. Biochanin A
and formononetin seem to be AhR agonists and may induce CYP1B1 and CYP1A1 [6] Elevation of
placental CYP1A1 activity, which is mediated by AhR, is linked with premature birth and other fetal
alterations in smoking women [70].
Some flavones (chrysin, baicalein, and galangin), naringenin and isoflavones (genistein, biochanin A)
are able to inhibit the activity of aromatase CYP19, which has a pivotal role in the production of estrogens,
reducing their synthesis [71]. Rutin, myricetin, isorhamnetin, p-coumaric acid, gallic acid, and caffeic acid
exert a sex-specific inhibition on CYP1A, CYP2A, CYP2E1 (Table 2), and CYP3A being higher in female
pigs than in male ones ([19] and cited literature), whereas quercetin-induced inhibition of CYP2E1 and
myricetin-induced inhibition of CYP3A are present only in male pigs ([19] and cited literature) (Table 2).
The activity of CYP2D2, which is higher in male rats versus females, and that of CYP3A is inhibited by
resveratrol) and isorhamnetin in both sexes ([19,72] and cited literature) (Table 2). In men and women, the
sexual dimorphism is not as evident ([19] and cited literature).
Both in humans and in non-human animals, some foods and beverages, such as Brassicaceae vegetables,
soya derivate products, citrus fruits, etc., induce UGT ([19] and cited literature). The activities of phase
II enzyme may be influenced by sex–gender, with disulphates, followed by 7-sulpho-4′-glucuronides
derivates being the main metabolites in male rats, whereas female rats produce more 7-glucuronides
([19] and cited literature). After ingestion of olive leaf extract or olive oil, the plasma concentration of HT
glucuronide, HT sulfate, and oleuropein aglycone glucuronide are higher in postmenopausal women
versus premenopausal women [73,74]. Plasma genistein glucuronide levels are higher (>2 fold) in female
than in male Sprague Dawley rats, and are also higher versus genistein aglycone in females but not
in males, although these data are not univocal [48]. Notably, some glucuronides of some phenolics
(e.g., daidzein and genistein) retain certain biological activities. In human hepatic microsomes, the
conjugation through UGT1A1 and UGT1A3 of resveratrol and pterostilbene is more efficient in females
than in male microsomes [75]. Glucuronides are more hydrophilic than their precursors, thus the passage
from intracellular to extracellular compartments needs transporters, building an interplay between UGT
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and efflux transporters. The COMT, which is more expressed in male individuals, [19] is inhibited, in vitro,
by epigallocatechin-3-gallate (EGCG) [76]. However, a single dose of EGCG does not impair the COMT of
red blood cells in healthy individuals [77]. A synthetic inhibitor of COMT (tolcapone) reduces the seeking
or consumption of ethanol, specifically in male high drinkers [78]. Importantly, phenols can regulate the
ratio between CYP enzyme/phase II enzymes, which can be a pivotal phenomenon for the life and death
of cells after carcinogens [16]. Among CYP, UGT, and phenols, there is a bidirectional interplay because
phenols may regulate the activity of CYP and UGT as they are also metabolized by them.
Some variability in phenol metabolism could depend on sexual hormones [48], and by microbiota
(see below).
4.3. Distribution
After absorption, a phenol is distributed into interstitial and intracellular fluids and tissues.
The distribution depends on molecules (lipid solubility, dimension, etc.) and individual characteristics
(vascular permeability, regional blood flow, and perfusion plasma proteins bindings, etc.). Phenols
binding to albumin or to other plasma proteins is an important determinant in phenols availability
and distribution. Information about sex–gender differences in human serum albumin levels is scarce,
although circulating levels of albumin are influenced by age, sex, and pregnancy [79]. Phenols may
bind serum proteins, and this may modify phenol distributions and induce phenol–drug interactions.
For example, casticin and resveratrol slightly displace naproxen from human albumin [80]. In vitro,
acacetin, apigenin, chrysin, luteolin, galangin, quercetin hesperetin, and naringenin aglycones may
inhibit the binding of warfarin [81]. Unfortunately, it is not known if the binding of phenols with
protein presents sexual dimorphisms or if it changes with pregnancy. In view of human sexual
dimorphism presented in Table 1, it is plausible that sex–gender differences in phenol distribution exist.
For example, the administration of grape seed phenols presents a different distribution in plasma,
brain, and liver of female and male rats [82] and that may affect the activities of flavanols in males and
in females.
4.4. Elimination
The conjugated forms are excreted in the urine [83]. After absorption of olive oil, kidney
elimination of HT and that of its major microbial metabolites homovanillyl alcohol are higher in
humans than in rats [84], indicating that the kidney elimination is species-dependent. The ingestion of
HT derivatives modifies the kidney elimination of dopamine, noradrenaline, normetanephrine, and
3-methoxytyramine, with the effect being larger in males (12-fold) than in females (1.5-fold), indicating
that interaction among phenols and catecholamines occur [85]. Human HT excretion is also influenced
by formulation [84]. Finally, urinary excretion of phenols depends on sex–gender and on age. In an
elderly Italian population (more than 56% have impaired renal function), the total urinary excretion
of phenols decreases with age and is greater in men than in women [86]. Upon the commencement
of daily consumption of soy milk, urinary elimination of isoflavone conjugates is larger in women
than in men; however, only in women there is a progressive reduction in excretion of genistein and
daidzein [87]. In fact, it is not known if urinary microbiota influences the phenol elimination in a
sex–gender-specific way. This could be plausible because adult men and women have different urinary
microbiota [88]. The female microbiota depends on sex hormones. A large abundance of Clostridia
and Ruminoccocaceae genera is linked with urinary estrogens [89]. Intriguingly, the bladder microbiota
of pregnant women resembles those of perimenopausal women [88]. It varies in overactive bladders
with and without urgency urinary incontinence [88], and in major depression [90], a mood disturb that
mainly affects women versus men [91].
Phenols can also be eliminated in the feces or deconjugated by gut microbiota (see below and
Figure 2), which results in their reabsorption and enterohepatic recirculation [83]. Finally, they can be
eliminated as CO2 by the lungs [83].
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5. Microbiota
The intestinal microbiota is a complex and dynamic ecosystem that strictly cooperates with the
host to maintain host homeostasis and it depends on numerous environmental (diet, drugs, etc.) and
individual factors, including sex–gender; thus, it is highly personalized by life experiences ([19,92] and
cited literature).
Healthy women have higher intestinal microbial diversity and a relative abundance of specific
taxa versus healthy men [93,94]. Interestingly, age has different effects in males versus females, with the
age effect on Streptococcus salivarius being female-specific [95]). The sex–gender diversity of microbiota
also depends on body dimensions. The abundance of the Bacteroides is lower in obese men than in
obese women, whereas B. plebeius is higher only in obese men. Possessing a body mass index (BMI) of
over 33 changes the Firmicutes/Bacteriodetes ratio [94]. Women and men with a BMI < 33 do not present
significant differences. The gut microbiota diverges in premenopausal and postmenopausal women,
the latter have a gut microbiota that is very similar to that of men [96]. In postmenopausal women,
genistein and glycitin modify the intestinal microbiota by elevating and lowering the concentration
of the Bifidobacterium and Clostridiaceae, respectively [[19] and cited literature]. Bilateral ovariectomy
causes dysbiosis, increasing the abundance of Clostridium bolteae [95]. Gut microbiota composition
in women is also influenced by oral contraceptives, which alter both microbial species abundance
and functional pathways [95]. Not only do estrogens impact on microbiota but microbiota itself may
regulate circulating estrogens [97]. The bacterial β-glucuronidases deconjugate a variety of endogenous
molecules and numerous xenobiotics, including sexual hormones and phenols [98]. Starting from
flavonoids, humans produce equol, enterolactone, and enterodiol ([52] and cited literature). S-equol is
produced only by some subjects ([52] and cited literature), whereas other individuals, who consume soy,
may produce O-desmethylangolensin via 2′-dehydro-O-demethylangolensin. Moreover, Clostridium
and E. ramulus species induce formation of flavanones aglycones and further degradation in the
colon ([52] and cited literature). The gut microbiota, through Bacteroides and Clostridium species,
transforms lignans into estrogenic enterolactone and enterodiol ([52] and cited literature). Clostridium
scindens convert glucorticoids to androgens [99]. Blueberry supplementation (rich in anthocyanins and
phenolic acids) alters gut microbiota, increasing the Bacteroidetes and decreasing the Firmicutes, with
the effect being greater in females than in males. Beside the five genera unique to males, Clostridium,
Corynebacterium, and Facklamia are elevated, while Ruminococcus and RF39 are lowered. In female mice,
Adlercreutzia, Coprococcus, Mogibacteriaceae, Turicibacter, and S24-7 are elevated, while Anaerotruncus,
Christensenellaceae, Ruminococcus, Mucispirillum, and Staphylococcus are lowered in the blueberry-fed
groups [100].
A marker of gut dysbiosis, trimethylamine N-oxide (TMAO) is negatively related with a Mediterranean
Diet in a way characterized by an evident sexual dimorphism [101]. Dietary components present in
Cruciferae inhibit the synthesis of TMAO through inhibition of the flavin-containing monooxygenase form
3 [102], whose expression depends on sexual hormones [102,103].
The above results indicate that a bidirectional interaction co-exists among phenols and the
intestinal micro-organisms.
Gut, vaginal, and oral microbiota changes during pregnancy [104], but it is not known if they
change the pharmacokinetics of phenols.
Globally, the microbiota is important and relevant in the biotransformation of phenols and their
metabolic products, in turn, can favor the growth of beneficial gut inhabitants, able also to reduces the
growth of microbiological agents that can produce dysbiosis ([19] and cited literature). In this context,
we recall that numerous phenols have antimicrobial activity, and thus, this may modify their own
bacterial metabolism. Therefore, phenols and their metabolites could positively modulate intestinal
bacterial populations ([52] and cited literature]). Less it is known about the importance of urinary
microbiota in phenols’ pharmacokinetics.
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In conclusion, the biodiversity and richness of, at least, intestinal microbiota, are crucial for human
health in consideration of the possible beneficial effects of adsorbed vegetable foods and beverages as
well as of botanicals including phenols.
6. Interactions
It is hard to make a diagnosis of a supplement–drug interaction because most patients under-report
the consumption of nutraceuticals to their physicians [105]. This is especially of interest for women,
because they use more supplements and drugs than men [106,107]. However, these are not univocal
data because in inpatients, potential interactions are linked with the male sex [108], and are also linked
with older age and elevated consumption of supplements and/or drugs [108].
Supplement–drug interactions are mainly pharmacokinetic and most of them are linked with CYP
and UGT because they metabolize more than 90% of prescribed drugs [109]; however, drug uptake/efflux
transporters, and albumin binding are also involved [45]. Relevantly, 70% of drugs are metabolized
through CYP3A4, that it is higher expressed in females; thus, the induction or inhibition of CYP3A4
can occur to lower efficacy or to toxic effects of numerous pharmacological medications, including oral
contraceptives [110]. St John’s wort was banned by the French Ministry of Health [111] because it may
interact with antidepressants, potentially causing fatal serotonin syndrome [112]. Considering that
depression is more common in women [91], this could aggravate the risk in women who take St. John’s
wort. Indeed, there are also pharmacodynamic interactions resulting either in a decrease or increase in
response. The most studied pharmacodynamic botanical–drug interactions regards antithrombotic
and anticoagulant drugs [113]. Indeed, in healthy individuals, flavan-3-ol-enriched dark chocolate
reduces postprandial platelet function versus standard dark chocolate, in a sex–gender-dependent
way; having a major effect in men than in women [114].
Finally, after indomethacin, intestinal permeability increases in both sexes, but alteration in fecal
bacterial diversity is present only in women. After discontinuation of indomethacin, these changes
are reversible [93]. At the moment, there is lower awareness of the importance of microbiota as a site
of phenol–drug interactions. However, these interactions could be very frequent and may occur in a
sex-specific way, thus the new term: “pharmacomicrobiomics” [92] appears to be highly appropriate.
7. Development: Pregnancy, Lactation, and Developmental Trajectory
It is recognized that early life (prenatal and neonatal) events have a major role in shaping disease
risk (obesity, diabetes, and cardiovascular disease, etc.) in adulthood [21] and this seems to occur, at least
in some cases, in sex-dimorphic ways ([115] and cited literature). In particular, the expression levels of
the DNA methyltransferases (DNMT) are sexually divergent from blastocysts to adult life. DNMT 1,
3a, and 3b are down-regulated by progesterone ([115] and cited literature), whereas intra-hippocampal
infusion of estradiol elevates DNMT3a and 3b expression and also alters histone deacetylase ([115]
and cited literature).
7.1. Pregnancy
The use of prescription drugs in pregnancy generated two great tragedies (thalidomide and
diethylstilbestrol) [116], and this creates a great fear regarding prescription drugs that leads women
to use “natural and safe” alternatives, as testified by the large number of pregnant women that use
botanicals. In Australia, the prevalence ranges from 14% to 57% [117], whereas it is around 57.8% in
the UK [118]. In Italy, the following botanicals chamomile, licorice, fennel, aloe, valerian, echinacea,
almond oil, propolis, and cranberry are the most widely used [119], whereas in the USA, the most
used herbs are ginger, cranberry, valerian, raspberry, and chamomile [120]. Licorice supplements are
also extensively used in Denmark [121]. However, studies on natural alternatives in pregnancy and
lactation are few [122]. Thus, much of the information has very little scientific support. Consequentially,
the efficacy and safety profiles of phenols are alarming [123]. In this context, one should know if
the individual phenol crosses the placenta (genetically it has the same sex as the fetus), the rate and
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amount of phenols that reach the fetus, the duration and timing of exposure, and the distribution
characteristics in different fetal tissues. In addition, herbal products are often co-administered with
prescription drugs, raising concerns about possible interactions [124].
Pharmacological response in pregnancy may vary in consideration of the numerous physiological
changes induced by pregnancy. Briefly, it is observed a reduction of blood albumins, and an increase in
total body water and plasma volume ([125] and cited literature), affecting the distribution. A reduction
in gastrointestinal motility is also observed, as is an increase in gastric pH (impacting absorption).
In addition, the glomerular filtration rate is increased (impacting renal elimination). Changes in the
activity of drug metabolizing enzymes are also described and these changes together with placental
enzymes influence the metabolism ([125] and cited literature).
Numerous phenols cross the placenta [19,126,127], and some data suggest that the fetuses tend to
retain them longer than the mothers do [126]. Importantly, soy intake elevates daidzein and genistein
in amniotic fluid in a dose-dependent manner. This is especially true in the amniotic-fluid-containing
female fetuses [[128] and cited literature]. This suggests a possible differential metabolic handling of
phenols in male and female fetuses [128].
Analysis of 7928 boys, born from mothers that consume a vegetarian diet rich in phytoestrogen,
indicates that the vegetarian diet is associated with an increased risk of hypospadias [129]. In women, a
high dietary isoflavone intake may reduce fertility [130]. Paradoxically, the use of dietary phytoestrogens
is positively related to live-birth rates in assisted reproductive technology [131]. An association between
high serum isoflavones levels and the risk of central precocious puberty has been observed in Korean
girls [132].
The consumption of fenugreek (Trigonella foenum graecum) in pregnancy may induce congenital
malformations and death [133,134]. In male rats, mice, and rabbits, fenugreek may induce testicular
toxicity and anti-fertility effects, while it alters fertility, implantation, and abortions in females [134].
Prenatal exposure to St. John’s wort increases fetal malformations [135]. Licorice may induce the
so-called mineralocorticoid-excess syndrome, inhibiting 11-hydroxysteroid dehydrogenase type 2 [121].
Licorice use may contribute to an increased risk of preeclampsia [136], miscarriage [119], and preterm
birth [137]. It is relevant to recall that the side effects of licorice are more frequent in non-pregnant
women than in men [138].
Ginger (Zingiber officinale) is used to treat nausea and also has prokinetic effects. It contains gingerols
and shogaols, which exert anticholinergic activity (muscarinic receptors M3) and antiserotonergic
receptor versus 5-hydroxytryptamine receptor 3 [6]. The metabolite, 6-gingerol, may interact with
CYP3A4 and CYP2C9 [139], suggesting potential drug–herb interactions. Ginger seems to enhance
testosterone production [140] and may alter fetal testosterone metabolism [141]. In addition, ginger
seems to decrease platelet aggregation; however, these are not univocal data [142]. If so, inhibition of
platelet aggregation may elevate the probability of bleeding in the postpartum.
In line with previous observations, low maternal adherence to a Mediterranean diet during
pregnancy is associated with DNA hypomethylation at birth in female babies [143]. Interestingly,
some phenols such as EGCG may modify the ER activity modifying DNA hypomethylation and
histone deacetylation [144], whereas curcumin inhibits histone deacetylation. Flavonoids, in particular
isoflavones, flavonols, and catechins, are regulators of the epigenome through DNA methylation,
histone acetylation, and chromatin alterations [144]. Globally, the above data suggest that maternal
exposure during pregnancy may affect the epigenome.
The side effects of botanicals are also present after topical administration. In particular, topical
administration of aloe or almond oil in the prevention or reduction of striae gravidarum may produce
a rash and itching [119]. In almond oil users, miscarriages, preterm labors, and pre-term birth are more
frequent than in non-users [119,145]. Finally, microbiota changes throughout pregnancy show that the
bacterial diversity is more pronounced during the third trimester ([19] and cited literature), indicating
the need to consider it during studies.
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In view of the impressive number of plants used during pregnancy and the lack of knowledge about
this issue, there is an urgent need to rationalize the use of botanicals in pregnant women considering
the sex of the fetus, pharmacokinetics changes, and their potential clinical impact. Immediate attention
of regulatory authorities is required because the use of botanicals during pregnancy continues to be a
great concern for both women and babies’ health.
7.2. Lactation
Breastfeeding women might use prescription drugs or botanical products for postpartum
conditions and to induce milk production [146]. In many countries, the use of herbal galactagogues
is passed down from generation to generation [146]. Among lactating women, dietary/botanical
supplements have not been well-studied. Therefore, many more clinical trials are essential to expand
our current knowledge of these products and to develop recommendations [146], for the safety of
infants (in consideration of their sex), regarding their potential effects on quantity and quality of
milk [147].
7.3. Galactagogues Based on Herbs
There are numerous “natural” Galactagogues based on herbs [148] and they are perceived as
safe ([6] and cited literature). Despite the use of herbal galactagogues (Trigonella foenum, Foeniculum
vulgare, Anethum graveolens, Pimpinella anisum, Nigella sativa, Vitex agnus-castus, Cnicus benedictus,
Silybum marianum, (Galega officinalis), Coleus amboinicus Lour, Althaea officinalis, Urtica dioica), scant
clinical evidence exists regarding their effectiveness and safety profile [149]. As much as 45% of nursing
mothers who used fenugreek reported adverse reactions [150], with diarrhea and hepatomegaly being
the most frequent [151]. The use of Galega officinalis is not validated by any well-conducted trials;
however, its use might cause hypoglycemia [152].
7.4. Breast Milk
Human milk is characterized by the presence of a number of factors that are biologically active
such as microbes and antimicrobial molecules, functional fatty acids, hormones, oligosaccharides, and
stem cells etc. Its composition changes among mothers and during lactation and is also influenced by
maternal factors (for instance, diet, stress, BMI) and infant factors, such as sex, suggesting that there
are sex-specific requirements during lactation for optimal development ([153] and cited literature).
Interestingly, opposite-sex twins are smaller than same-sex twins when breastfed, as maternal milk
cannot simultaneously be tailored for both sexes ([153] and cited literature). Moreover, mothers of
male babies produce a more caloric milk (25%) than mothers of female infants [154]. This could be
attributed to greater growth rates of male versus to female babies. However, in Northern Kenya,
economically self-sufficient mothers breastfeed sons more frequently and produce breast milk with a
higher fat concentration for sons than for daughters. Vice versa, poor mothers breastfeed daughters
more frequently than sons and produce a milk with a more elevated fat amount for daughters compared
to sons [155]. These results stress the relevance and importance of social factors on milk production
and composition.
Botanical compounds must reach human milk to affect babies. Some phenols such as quercetin are
found in the milk [156], whereas soy isoflavones are not effectively transferred in the human milk ([157]
and cited literature). These findings demonstrate the importance of chemical structure to be transported
into the milk. BCRP plays a relevant role in milk composition participating in its bioavailability and
actively affecting the secretion of endogenous molecules and xenobiotics [158]. As already mentioned,
some phenols (extracts of soybean, Gymnema sylvestre, black cohosh, passion flower, and rutin) strongly
inhibit BCRP, while chlorella, milk thistle, and Siberian ginseng extracts are weak inhibitors [159].
Coumestrol is the most potent inhibitor among the tested isoflavonoids [159]. Consequentially, phenols
may greatly elevate the availability of BCRP substrates. Finally, the composition of milk microbiota is
sex-specific [160], but these are not univocal data [161]; the presence of numerous confounders such as
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the newborn feeding pattern, domestic water, use of antibiotics in pregnancy and etc. can all affect the
composition of milk microbiota (Figure 3) [162]. Interestingly, human milk microbiota may function as
a metabolic adaptor. For example, it may compensate for the human milk protein decline, increasing
the abundance of bacteria that have genetic software to synthesize amino acids [162].
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In conclusion, the maternal milk is the best choice for the feeding of infants as its composition fits
with the specific needs of each particular infant (gestational age, time of the day, geographical location,
environment, etc.) in a sex-specific manner. This ability indicates that maternal milk is a personalized
food source [163].
7.5. Soy-Milk Formula
Development is one of the most critical periods for endocrine-disrupting exposure. Thus, certain
concerns about the safety profile of soy-formula are not surpris ng. Soy-milk formula should be an
alternative to bovine-milk-formula for infants, which have milk allergy or lactose intolerance. However,
the consumption of soy-formula in the USA is estimated to be about 25% of the formula market [157].
The American Academy of Pediatrics, the European Society for Pediatric Gastroenterology Hepatology,
and the Nutrition Committee on Nutrition recommend the consume of soy-formula only in true
milk allergies r lactose intolerance [157]. The US National Toxicology Programme’s Istance on
soy-milk-formula [164] sustains that there is a ‘minimal concern for adverse developmental effects’.
However, it is important to recall that, in humans, the knowledge of the tardive effects of soy-milk is
limited and of poor quality [157]. Soy-formula intake is linked with altered age at menarche [165,166].
However, data on menarche age are not univocal ([157] and cited literature). A recent clinical
retrospective cohort trial found that young women fed with i fan soy-formula rep rt longer menstrual
bleeding and more menstrual discomfort than those who were fed with a non-soy based formula
([157] and cited literature). Soy-formula intake seems to be a risk factor for uterine fibroids [167] and
endometriosis ([157,168] and cited literature). A recent trial reports estrogenized vaginal epithelium in
females fed with soy-formula in their first months of life ([157] and cited literature), but other studies
do not find link between soy-infant-formula and developmental reproduct ve para eters ([157]
and cited literature). Notably, a study on mice reports that the neonatal administration of genistein
at 18 months increases the incidence of uterine adenocarcinoma, suggesting that genistein exposure
during critical periods of differentiation may be cancerogenic [169]. The dose of isoflavones ingested by
neonates fed with soy-formula is very high, reaching plasma levels even higher than those reported for
Japanese men fed with a soy-bas d diet [170,171] and xceed 13,000–22,000 times their own endogenous
estrogen ([157] and cited literature), altering reproductive hormones [172]. Soy-formula fed infants
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have higher urine concentrations of isoflavones than cow-milk-formula-fed infants [173]. In contrast,
infants fed with cow’s–milk-formula or human breast milk have low plasma isoflavone levels ([157]
and cited literature).
The soy-fed babies’ milk microbiota diverges in comparison with human milk and cow-formula-fed
babies because they have less Bifidobacteria [162]. In fact, at 3–4 months of age, Caucasian male and
female infants born from asthmatic women have fewer gut Lactobacilli and Bacteroidaceae [174].
Formula-fed babies harbor bacteria capable of making a very different set of amino acids that are scarce
in formula [162]. Breastfeeding formula ingredients and maternal gestational weight gain have specific
effects on gut microbiota [162]. For example, soy-formula is positively associated with Lachnospiraceae,
whereas breastfed infants have more Bifidobacterium and Lactobacillus.
Current guidelines do not contain diverse nutritional approaches or requirements for male and
female human infants [175], although human male preterm neonates respond better than females to
preterm-enriched formula to meet higher preterm requirements ([153] and cited literature).
The use of soy-based formulas without a real medical need should be carefully examined. Parents
should be informed beforehand about the possible estrogenic effects of soy-based formula during
infancy, even if its long-term health effects remain the subject of debate.
7.6. Developmental Trajectory
Roseboom et al. [176] provided evidence that different programming outcomes depend on the
time of exposure during pregnancy trimesters, and in some cases they may depend on sex [177].
In other words, some sex–gender differences in adult life may origin during prenatal and neonatal life.
At this regard, we recall that some placentation processes may be sex-specific [178–180]. Nowadays,
it is clarified that the prenatal and postnatal life environments, including diet, changes determine
both immediate and long-term effects that can be major factors in addressing the risk of adult disease,
including susceptibility to develop obesity, diabetes, cardiovascular diseases, etc. [115,181]. Indeed,
long-term consequences of modifications in the early life environment are linked with adult mortality
and expected lifespan in men and women [177]. Interestingly and relevantly, these processes occur in a
sexually-dimorphic way [115]. Early phytoestrogens exposure seems to be associated with the age of
puberty; however, the direction of this link seems to depend on the single phytoestrogen [182].
Finally, assumption of licorice during pregnancy is related with a lower intelligence quotient, low
memory, and elevated risk of attention deficit in the children [183]; however, it is not clear if these
phenomena are influenced by the sex. The pubertal advancement observed in girls exposed to licorice
during the gestational period could be ascribed to glabridin, a compound with estrogenic activity
present in the licorice [183,184]. In particular, girls are taller and heavier, and have higher BMI for age,
while cortisol levels do not diverge [183,184]. Neonatal exposure to relevant amount of isoflavones
may affect female fertility in mice [185].
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Table 2. Activity of some phenols and herbs on drug metabolic enzymes and transporters.
Species Enzyme/Transporters Phenols/Herbs Type ofActivity References
Pig CYP 1A1 Genistein Inh [6]
Pig CYP 1A1 Daidzein Inh [6]
Pig CYP 1A1 Biochanin Ind [6]
Pig CYP 1A1 Equol Inh [6]
Pig CYP 1A1 Rutin Inh [17]
Pig CYP 1A1 Myricetin Inh [17]
Pig CYP 1A1 p-couamric acid Inh [17]
Pig CYP 1A1 Gallic acid Inh [17]
Pig CYP 1A1 Caffeic acid Inh [17]
Human CYP1A2 Echinacea purpurea Inh [186]
Human CYP1A2 Garlic oil = [187,188]
Human CYP1A2 Allium sativum Inh [189]
Human CYP1A2 Matricaria recutita Inh [190]
Human CYP1A2 Gongronema latifolium, Inh [189]
Human CYP1A2 Moringa oleifera Inh [189]
Human CYP1A2 CG (-)-catechin-3-O-gallate, GCG(-)-gallocatechin-3-O-gallate, EGCG Inh [191]
Human CYP1A2 Berberine Inh [192]
Rat CYP1A2 Genistein Inh [48] and cited literature
Human CYP1A Mangifera indica Inh [189]
Human cancer cell CYP1A4 Genistein Inh [48] and cited literature
Human CYP2B6 Allium sativum Inh [189]
Human CYP2B6 Mangifera indica Inh [189]
Human CYP2E1 Garlic oil Inh [187]
Human CYP2E1 Piper methysticum Inh [188]
Human CYP2E1 St John’s wort Ind [187]
Pig CYP2E1 Quercetin Inh (male) [19]
Pig CYP2E1 Rutin Inh [19]
Pig CYP2E1 Myricetin Inh [19]
Pig CYP2E1 p-couamric acid Inh [19]
Pig CYP2E1 Gallic acid Inh [19]
Pig CYP2E1 Caffeic acid Inh [19]
Rat CYP2C Genistein Inh [48] and cited literature
Human CYP2C8 Allium sativum Inh [189]
Human CYP2C8 Mangifera indica Inh [189]
Human CYP2C9 Mangifera indica Inh [189]
Human CYP2C9 Allium sativum Inh (2c9*1)
=
[193]
[189]
Human CYP2C9 Matricaria recutita Inh [190]
Human CYP2C9
(-)-epicatechin-3-O-gallate ECG, (-)-
epigallocatechin, EGC CG
(-)-catechin-3-O-gallate,
Inh [191]
Human CYP2C9 Berberine Inh [192]
Human CYP2C19 Achillea millefolium Inh [190]
Human CYP2C19 Ginkgo biloba Ind [194]
Rat CYP2D2 Isorhamnetin Inh [17,64]
Rat CYP2D2 Resveratrol Inh [72,195]
Human CYP2D6 Hydrastis Canadensis Inh [196]
Human CYP2D6 Allium sativum = [189,193]
Human CYP2D6 Garlic oil = [187,188]
Human CYP2D6 Cimicifuga racemosa Inh [188]
Human CYP2D6 Mangifera indica Inh [189]
Human CYP2D6 Alstonia boonei Inh [189]
Rat CYP2D6 Alstonia scholaris Inh [190]
Human CYP2D6 Matricaria recutita Inh [190]
Human CYP2D6 Picralima nitida Inh [189]
Human CYP2D6 Berberine Inh [192]
Human CYP3A4 St John’s wort IndInd
[45]
[187]
Human intestinal CYP3A4 Grapefruit juice Inh
=
[197]
Human liver CYP3A4intestinal CYP3A4 Echinacea purpurea
Inh
Ind
[186]
[198]
Rat CYP3A Genistein Inh [48] and cited literature
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Table 2. Cont.
Species Enzyme/Transporters Phenols/Herbs Type ofActivity References
Pig CYP3A Myricetin Inh (male) [17]
Human CYP3A4 Allium sativum Inh
=
[193]
[199]
Human CYP3A4 Matricaria recutita Inh [190]
Human CYP3A4 Picralima nitida Inh [189]
Human CYP3A4 Achillea millefolium Inh [190]
Human CYP3A4 CG (-)-catechin-3-O-gallate, GCG(-)-gallocatechin-3-O-gallate, EGCG Inh [191]
Human CYP3A4 Berberine Inh [192]
Human CYP3A5 Allium Sativum Inh
=
[193]
[199]
Sheep BCRP Genistein Ind [45]
Human Oatp1A2 Green tea extract Inh [200]
Human P-glycoprotein/MDR1 Garlic extract Ind [199]
Human P-glycoprotein/MDR1 St John’s wort Inh [45]
Rat P-glycoprotein/MDR1 St John’s wort Inh [45]
Human cancer cell
line UDP Genistein Ind [48] and cited literature
Human SULT Genistein Inh [48] and cited literature
Human COMT Epigallocatechin-3-gallate Inh [68]
Inh = inhibition; Ind = induction.
8. Conclusions
In view of the rapid increase in the global consumption of phenols, further insights into their
risks and benefits on health seem essential; thus, additional studies with individuals of all ages and
sex–genders are needed because the ratio risk/benefit is still unclear. Prescription drugs are marketed
only after approval from regulatory authorities, which occurs after accurate preclinical research and
after randomized clinical trials; this does not occur with the majority of marketed herbal products.
In view of overcome health problems, these studies should be performed also for the botanicals.
These studies must introduce sex-gender aspects in order to favor transition toward tailored nutrition
and medicine. Indeed, to design a personalized medicine, it is necessary to investigate the role of the
gut microbiota and to consider “Thrifty Phenotype Hypothesis” [21]; thus, the long-term effects of
phenols, especially when exposure occurs during prenatal and neonatal life, must be known. This
is especially true for phenols with hormonal activities. Finally, the social environmental should be
considered in the design of studies.
Author Contributions: Conceptualization F.F.; Research and analyzed the literature A.R. and I.C.; Writing—Original
I.C. and F.F.; Draft Preparation I.C. and A.R.; Writing including interpretations, review, and editing, I.C., A.R., and F.F.
All authors approve the final version of the manuscript, ensure the accuracy and integrity of the work, and agree to
be accountable for all aspects of the work.
Funding: This research was partially funded by a grant of INAIL “Bando BRIC 2016”.
Conflicts of Interest: The authors declare no conflict of interest
References
1. Barnes, P.M.; Bloom, B.; Nahin, R.L. Complementary and alternative medicine use among adults and children:
United States, 2007. Natl. Health Stat. Rep. 2008, 12, 1–23.
2. Matulka, R.A. Dietary Supplements in the U.S. and Abroad: Similarities and Differences; Burdock Group: Orlando,
FL, USA, 2016.
3. Smith, T.; Kawa, K.; Eckl, V.; Morton, C.; Stredney, R. Herbal supplement sales in US increased 8.5% in 2017,
topping $8 billion. HerbalGram 2018, 119, 62–71.
4. National Institute of Health. Dietary Supplement Label Database. Available online: https://dsld.nlm.nih.
gov/dsld/ (accessed on 25 November 2018).
Nutrients 2019, 11, 1637 16 of 25
5. National Institute of Health. Complementary, Alternative, or Integrative Health: What’s in a Name? National
Center for Complementary and Integrative Medicine, Ed.; NCCIH: Washington, DC, USA, 2016.
6. Dietz, B.M.; Hajirahimkhan, A.; Dunlap, T.L.; Bolton, J.L. Botanicals and their bioactive phytochemicals for
women’s health. Pharmacol. Rev. 2016, 68, 1026–1073. [CrossRef] [PubMed]
7. Government of Canada. What Is Gender? What Is Sex? Canadian Institutes of Health Research. Available
online: http://www.cihr-irsc.gc.ca/e/48642.html (accessed on 26 April 2019).
8. WHO. Gender, Equity and Human Rights. Available online: https://www.who.int/gender-equity-rights/
understanding/gender-definition/en/ (accessed on 26 April 2019).
9. European Institute for Gender Equality. Concepts and Definitions. Available online: https://eige.europa.eu/
gender-mainstreaming/concepts-and-definitions (accessed on 26 April 2019).
10. Australian Government. Australian Government Guidelines on the Recognition of Sex and Gender Attorney
General’s Department. Available online: https://www.ag.gov.au/Pages/default.aspx (accessed on 26 April 2019).
11. Marino, M.; Masella, R.; Bulzomi, P.; Campesi, I.; Malorni, W.; Franconi, F. Nutrition and human health from
a sex-gender perspective. Mol. Asp. Med. 2011, 32, 1–70. [CrossRef] [PubMed]
12. Regitz-Zagrosek, V. Sex and Gender Differences in Pharmacology; Springer: Berlin, Germany, 2012; Volume 214.
13. Rienks, J.; Barbaresko, J.; Nothlings, U. Association of isoflavone biomarkers with risk of chronic disease and
mortality: A systematic review and meta-analysis of observational studies. Nutr. Rev. 2017, 75, 616–641.
[CrossRef] [PubMed]
14. Rietjens, I.; Louisse, J.; Beekmann, K. The potential health effects of dietary phytoestrogens. Br. J. Pharmacol.
2017, 174, 1263–1280. [CrossRef]
15. Cory, H.; Passarelli, S.; Szeto, J.; Tamez, M.; Mattei, J. The role of polyphenols in human health and food
systems: A mini-review. Front. Nutr. 2018, 5, 87. [CrossRef]
16. Tresserra-Rimbau, A.; Lamuela-Raventos, R.M.; Moreno, J.J. Polyphenols, food and pharma. Current
knowledge and directions for future research. Biochem. Pharmacol. 2018, 156, 186–195. [CrossRef]
17. Kim, Y.S.; Unno, T.; Kim, B.-Y.; Park, M.-S. Sex differences in gut microbiota. World J. Mens Health 2019,
37, e15. [CrossRef]
18. Elderman, M.; de Vos, P.; Faas, M. Role of microbiota in sexually dimorphic immunity. Front. Immunol. 2018,
9, 1018. [CrossRef]
19. Campesi, I.; Marino, M.; Cipolletti, M.; Romani, A.; Franconi, F. Put “gender glasses” on the effects of
phenolic compounds on cardiovascular function and diseases. Eur. J. Nutr. 2018, 57, 2677–2691. [CrossRef]
[PubMed]
20. Corella, D.; Coltell, O.; Portoles, O.; Sotos-Prieto, M.; Fernandez-Carrion, R.; Ramirez-Sabio, J.B.;
Zanon-Moreno, V.; Mattei, J.; Sorli, J.V.; Ordovas, J.M. A guide to applying the sex-gender perspective to
nutritional genomics. Nutrients 2018, 11, 4. [CrossRef] [PubMed]
21. Hales, C.N.; Barker, D.J.; Clark, P.M.; Cox, L.J.; Fall, C.; Osmond, C.; Winter, P.D. Fetal and infant growth and
impaired glucose tolerance at age 64. BMJ 1991, 303, 1019–1022. [CrossRef]
22. Weng, J.K. The evolutionary paths towards complexity: A metabolic perspective. New Phytol. 2014, 201,
1141–1149. [CrossRef] [PubMed]
23. Pacifico, S.; Piccolella, S.; Galasso, S.; Fiorentino, A.; Kretschmer, N.; Pan, S.P.; Bauer, R.; Monaco, P.
Influence of harvest season on chemical composition and bioactivity of wild rue plant hydroalcoholic extracts.
Food Chem. Toxicol. 2016, 90, 102–111. [CrossRef]
24. Rieger, G.; Muller, M.; Guttenberger, H.; Bucar, F. Influence of altitudinal variation on the content of phenolic
compounds in wild populations of Calluna vulgaris, Sambucus nigra, and Vaccinium myrtillus. J. Agric.
Food Chem. 2008, 56, 9080–9086. [CrossRef] [PubMed]
25. Schilter, B.; Andersson, C.; Anton, R.; Constable, A.; Kleiner, J.; O’Brien, J.; Renwick, A.G.; Korver, O.; Smit, F.;
Walker, R. Guidance for the safety assessment of botanicals and botanical preparations for use in food and
food supplements. Food Chem. Toxicol. 2003, 41, 1625–1649. [CrossRef]
26. Simpraga, M.; Takabayashi, J.; Holopainen, J.K. Language of plants: Where is the word? J. Integr. Plant Biol.
2016, 58, 343–349. [CrossRef]
27. Dicke, M.; van Loon, J.J.; Soler, R. Chemical complexity of volatiles from plants induced by multiple attack.
Nat. Chem. Biol. 2009, 5, 317–324. [CrossRef]
28. Perez-Jimenez, J.; Fezeu, L.; Touvier, M.; Arnault, N.; Manach, C.; Hercberg, S.; Galan, P.; Scalbert, A. Dietary
intake of 337 polyphenols in French adults. Am. J. Clin. Nutr. 2011, 93, 1220–1228. [CrossRef]
Nutrients 2019, 11, 1637 17 of 25
29. Jefferson, W.N.; Patisaul, H.B.; Williams, C.J. Reproductive consequences of developmental phytoestrogen
exposure. Reproduction 2012, 143, 247–260. [CrossRef]
30. Romani, A.; Lapucci, C.; Cantini, C.; Ieri, F.; Mulinacci, N.; Visioli, F. Evolution of minor polar compounds
and antioxidant capacity during storage of bottled extra virgin olive oil. J. Agric. Food Chem. 2007, 55,
1315–1320. [CrossRef]
31. Rodriguez-Morato, J.; Boronat, A.; Kotronoulas, A.; Pujadas, M.; Pastor, A.; Olesti, E.; Perez-Mana, C.;
Khymenets, O.; Fito, M.; Farre, M.; et al. Metabolic disposition and biological significance of simple phenols
of dietary origin: Hydroxytyrosol and tyrosol. Drug Metab. Rev. 2016, 48, 218–236. [CrossRef]
32. Zimmermann, P.; Zentgraf, U. The correlation between oxidative stress and leaf senescence during plant
development. Cell. Mol. Biol. Lett. 2005, 10, 515–534.
33. Ben Ahmed, Z.; Yousfi, M.; Viaene, J.; Dejaegher, B.; Demeyer, K.; Mangelings, D.; Vander Heyden, Y.
Seasonal, gender and regional variations in total phenolic, flavonoid, and condensed tannins contents and in
antioxidant properties from Pistacia atlantica ssp. leaves. Pharm. Biol. 2017, 55, 1185–1194. [CrossRef]
34. Ruuhola, T.; Nybakken, L.; Randriamanana, T.; Lavola, A.; Julkunen-Tiitto, R. Effects of long-term
UV-exposure and plant sex on the leaf phenoloxidase activities and phenolic concentrations of Salix
myrsinifolia (Salisb.). Plant Physiol. Biochem. 2018, 126, 55–62. [CrossRef]
35. Xu, X.; Zhao, H.; Zhang, X.; Hanninen, H.; Korpelainen, H.; Li, C. Different growth sensitivity to enhanced
UV-B radiation between male and female Populus cathayana. Tree Physiol. 2010, 30, 1489–1498. [CrossRef]
36. Koczka, N.; Moczar, Z.; Stefanovits-Banyai, E.; Ombodi, A. Differences in antioxidant properties of ginkgo
leaves collected from male and female trees. Acta Pharm. 2015, 65, 99–104. [CrossRef]
37. Galambosi, B.; Galambosi, Z.S.; Slacanin, I. Comparison of natural and cultivated roseroot (Rhodiola rosea
L.) roots in Finland. J. Med. Spice Plants 2007, 12, 141–147.
38. Wang, L.; Sun, R.; Zhang, Q.; Luo, Q.; Zeng, S.; Li, X.; Gong, X.; Li, Y.; Lu, L.; Hu, M.; et al. An update on
polyphenol disposition via coupled metabolic pathways. Expert Opin. Drug Metab. Toxicol. 2019, 15, 151–165.
[CrossRef]
39. Morton, M.S.; Arisaka, O.; Miyake, N.; Morgan, L.D.; Evans, B.A. Phytoestrogen concentrations in serum
from Japanese men and women over forty years of age. J. Nutr. 2002, 132, 3168–3171. [CrossRef]
40. Franconi, F.; Campesi, I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: Interaction with
biological differences between men and women. Br. J. Pharmacol. 2014, 171, 580–594. [CrossRef]
41. Franconi, F.; Campesi, I. Sex and gender influences on pharmacological response: An overview. Expert Rev.
Clin. Pharmacol. 2014, 7, 469–485. [CrossRef]
42. Yang, L.; Li, Y.; Hong, H.; Chang, C.W.; Guo, L.W.; Lyn-Cook, B.; Shi, L.; Ning, B. Sex Differences in the expression
of drug-metabolizing and transporter genes in human liver. J. Drug Metab. Toxicol. 2012, 3, 1000119. [CrossRef]
43. Fernandes, I.; de Freitas, V.; Mateus, N. Anthocyanins and human health: How gastric absorption may
influence acute human physiology. Nutr. Aging 2014, 2, 1–14.
44. Couteau, D.; McCartney, A.L.; Gibson, G.R.; Williamson, G.; Faulds, C.B. Isolation and characterization of
human colonic bacteria able to hydrolyse chlorogenic acid. J. Appl. Microbiol. 2001, 90, 873–881. [CrossRef]
45. Murtaza, G.; Ullah, N.; Mukhtar, F.; Nawazish, S.; Muneer, S. Phytotherapeutics: The emerging role of
intestinal and hepatocellular transporters in drug interactions with botanical supplements. Molecules 2017,
22, 1699. [CrossRef]
46. Jia, X.; Chen, J.; Lin, H.; Hu, M. Disposition of flavonoids via enteric recycling: Enzyme-transporter coupling
affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J. Pharmacol.
Exp. Ther. 2004, 310, 1103–1113. [CrossRef]
47. Merino, G.; van Herwaarden, A.E.; Wagenaar, E.; Jonker, J.W.; Schinkel, A.H. Sex-dependent expression and
activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
Mol. Pharmacol. 2005, 67, 1765–1771. [CrossRef]
48. Yang, Z.; Kulkarni, K.; Zhu, W.; Hu, M. Bioavailability and pharmacokinetics of genistein: Mechanistic
studies on its ADME. Anticancer Agents Med. Chem. 2012, 12, 1264–1280. [CrossRef]
49. Coldham, N.G.; Sauer, M.J. Pharmacokinetics of [(14)C]Genistein in the rat: Gender-related differences,
potential mechanisms of biological action, and implications for human health. Toxicol. Appl. Pharmacol. 2000,
164, 206–215. [CrossRef] [PubMed]
50. Vieira, A.T.; Castelo, P.M.; Ribeiro, D.A.; Ferreira, C.M. Influence of oral and gut microbiota in the health of
menopausal women. Front. Microbiol. 2017, 8, 1884. [CrossRef] [PubMed]
Nutrients 2019, 11, 1637 18 of 25
51. Balan, P.; Chong, Y.S.; Umashankar, S.; Swarup, S.; Loke, W.M.; Lopez, V.; He, H.G.; Seneviratne, C.J. Keystone
species in pregnancy gingivitis: A snapshot of oral microbiome during pregnancy and postpartum period.
Front. Microbiol. 2018, 9, 2360. [CrossRef] [PubMed]
52. Marin, L.; Miguelez, E.M.; Villar, C.J.; Lombo, F. Bioavailability of dietary polyphenols and gut microbiota
metabolism: Antimicrobial properties. Biomed Res. Int. 2015, 2015, 905215. [CrossRef] [PubMed]
53. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols
in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S–242S. [CrossRef]
54. Di, L. The role of drug metabolizing enzymes in clearance. Expert Opin. Drug Metab. Toxicol. 2014, 10,
379–393. [CrossRef]
55. Hernandez, J.P.; Mota, L.C.; Huang, W.; Moore, D.D.; Baldwin, W.S. Sexually dimorphic regulation and
induction of P450s by the constitutive androstane receptor (CAR). Toxicology 2009, 256, 53–64. [CrossRef]
56. Lamba, V.; Lamba, J.; Yasuda, K.; Strom, S.; Davila, J.; Hancock, M.L.; Fackenthal, J.D.; Rogan, P.K.; Ring, B.;
Wrighton, S.A.; et al. Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6
genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 2003, 307, 906–922.
[CrossRef]
57. Uno, Y.; Takata, R.; Kito, G.; Yamazaki, H.; Nakagawa, K.; Nakamura, Y.; Kamataki, T.; Katagiri, T. Sex- and
age-dependent gene expression in human liver: An implication for drug-metabolizing enzymes. Drug Metab.
Pharmacokinet. 2017, 32, 100–107. [CrossRef]
58. Kawamoto, T.; Kakizaki, S.; Yoshinari, K.; Negishi, M. Estrogen activation of the nuclear orphan receptor
CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. Mol. Endocrinol. 2000, 14,
1897–1905. [CrossRef]
59. Bright, A.S.; Herrera-Garcia, G.; Moscovitz, J.E.; You, D.; Guo, G.L.; Aleksunes, L.M. Regulation of drug
disposition gene expression in pregnant mice with CAR receptor activation. Nucl. Recept. Res. 2016, 3, 101193.
[CrossRef] [PubMed]
60. Tolson, A.H.; Wang, H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.
Adv. Drug Deliv. Rev. 2010, 62, 1238–1249. [CrossRef] [PubMed]
61. Spruiell, K.; Jones, D.Z.; Cullen, J.M.; Awumey, E.M.; Gonzalez, F.J.; Gyamfi, M.A. Role of human pregnane
X receptor in high fat diet-induced obesity in pre-menopausal female mice. Biochem. Pharmacol. 2014, 89,
399–412. [CrossRef] [PubMed]
62. Sachar, M.; Kelly, E.J.; Unadkat, J.D. Mechanisms of CYP3A induction during pregnancy: Studies in HepaRG
cells. AAPS J. 2019, 21, 45. [CrossRef] [PubMed]
63. Chen, Y.; Tang, Y.; Guo, C.; Wang, J.; Boral, D.; Nie, D. Nuclear receptors in the multidrug resistance through
the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol. 2012, 83, 1112–1126.
[CrossRef] [PubMed]
64. Hukkanen, J. Induction of cytochrome P450 enzymes: A view on human in vivo findings. Expert Rev.
Clin. Pharmacol. 2012, 5, 569–585. [CrossRef] [PubMed]
65. Park, H.J.; Choi, J.M. Sex-specific regulation of immune responses by PPARs. Exp. Mol. Med. 2017, 49, e364.
[CrossRef] [PubMed]
66. Jalouli, M.; Carlsson, L.; Ameen, C.; Linden, D.; Ljungberg, A.; Michalik, L.; Eden, S.; Wahli, W.; Oscarsson, J.
Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: Influence of pituitary
and gonadal hormones. Endocrinology 2003, 144, 101–109. [CrossRef]
67. Dunn, S.E.; Ousman, S.S.; Sobel, R.A.; Zuniga, L.; Baranzini, S.E.; Youssef, S.; Crowell, A.; Loh, J.; Oksenberg, J.;
Steinman, L. Peroxisome proliferator-activated receptor (PPAR)α expression in T cells mediates gender
differences in development of T cell-mediated autoimmunity. J. Exp. Med. 2007, 204, 321–330. [CrossRef]
68. Mohammadi-Bardbori, A.; Bengtsson, J.; Rannug, U.; Rannug, A.; Wincent, E. Quercetin, resveratrol, and
curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). Chem. Res. Toxicol. 2012, 25,
1878–1884. [CrossRef]
69. Pastorkova, B.; Vrzalova, A.; Bachleda, P.; Dvorak, Z. Hydroxystilbenes and methoxystilbenes activate human
aryl hydrocarbon receptor and induce CYP1A genes in human hepatoma cells and human hepatocytes.
Food Chem. Toxicol. 2017, 103, 122–132. [CrossRef] [PubMed]
70. Stejskalova, L.; Pavek, P. The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon
receptor (AhR) in the placenta. Curr. Pharm. Biotechnol. 2011, 12, 715–730. [CrossRef] [PubMed]
Nutrients 2019, 11, 1637 19 of 25
71. Moon, Y.J.; Wang, X.; Morris, M.E. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism.
Toxicol. In Vitro 2006, 20, 187–210. [CrossRef] [PubMed]
72. Zendulka, O.; Totusek, J.; Sulcova, A. Intersexual differences in inhibitory influence of trans-resveratrol on
activity of cytochrome P450 2D2 in rats. Neuro Endocrinol. Lett. 2009, 30, 88–91. [PubMed]
73. Garcia-Villalba, R.; Larrosa, M.; Possemiers, S.; Tomas-Barberan, F.A.; Espin, J.C. Bioavailability of phenolics
from an oleuropein-rich olive (Olea europaea) leaf extract and its acute effect on plasma antioxidant status:
Comparison between pre- and postmenopausal women. Eur. J. Nutr. 2014, 53, 1015–1027. [CrossRef]
[PubMed]
74. Suarez, M.; Valls, R.M.; Romero, M.P.; Macia, A.; Fernandez, S.; Giralt, M.; Sola, R.; Motilva, M.J. Bioavailability
of phenols from a phenol-enriched olive oil. Br. J. Nutr. 2011, 106, 1691–1701. [CrossRef]
75. Dellinger, R.W.; Garcia, A.M.; Meyskens, F.L., Jr. Differences in the glucuronidation of resveratrol and
pterostilbene: Altered enzyme specificity and potential gender differences. Drug Metab. Pharmacokinet. 2014,
29, 112–119. [CrossRef] [PubMed]
76. Zhu, B.T.; Shim, J.Y.; Nagai, M.; Bai, H.W. Molecular modelling study of the mechanism of high-potency
inhibition of human catechol-O-methyltransferase by (−)-epigallocatechin-3-O-gallate. Xenobiotica 2008, 38,
130–146. [CrossRef]
77. Lorenz, M.; Paul, F.; Moobed, M.; Baumann, G.; Zimmermann, B.F.; Stangl, K.; Stangl, V. The activity of
catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG)
in vivo. Eur. J. Pharmacol. 2014, 740, 645–651. [CrossRef]
78. McCane, A.M.; DeLory, M.J.; Timm, M.M.; Janetsian-Fritz, S.S.; Lapish, C.C.; Czachowski, C.L. Differential
COMT expression and behavioral effects of COMT inhibition in male and female Wistar and alcohol
preferring rats. Alcohol 2018, 67, 15–22. [CrossRef]
79. Fanali, G.; di Masi, A.; Trezza, V.; Marino, M.; Fasano, M.; Ascenzi, P. Human serum albumin: From bench to
bedside. Mol. Aspects Med. 2012, 33, 209–290. [CrossRef] [PubMed]
80. Mohos, V.; Bencsik, T.; Boda, G.; Fliszar-Nyul, E.; Lemli, B.; Kunsagi-Mate, S.; Poor, M. Interactions of
casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4
enzymes. Biomed. Pharmacother. 2018, 107, 777–784. [CrossRef] [PubMed]
81. Poór, M.; Li, Y.; Kunsági-Máté, S.; Petrik, J.; Vladimir-Kneževic´, S.; Ko˝szegi, T. Molecular displacement of
warfarin from human serum albumin by flavonoid aglycones. J. Lumin. 2013, 142, 122–127. [CrossRef]
82. Margalef, M.; Pons, Z.; Iglesias-Carres, L.; Arola, L.; Muguerza, B.; Arola-Arnal, A. Gender-related similarities
and differences in the body distribution of grape seed flavanols in rats. Mol. Nutr. Food Res. 2016, 60, 760–772.
[CrossRef] [PubMed]
83. Bircsak, K.M.; Aleksunes, L.M. Interaction of Isoflavones with the BCRP/ABCG2 drug transporter. Curr. Drug
Metab. 2015, 16, 124–140. [CrossRef] [PubMed]
84. Visioli, F.; Galli, C.; Grande, S.; Colonnelli, K.; Patelli, C.; Galli, G.; Caruso, D. Hydroxytyrosol excretion
differs between rats and humans and depends on the vehicle of administration. J. Nutr. 2003, 133, 2612–2615.
[CrossRef] [PubMed]
85. Dominguez-Perles, R.; Aunon, D.; Ferreres, F.; Gil-Izquierdo, A. Physiological linkage of gender, bioavailable
hydroxytyrosol derivatives, and their metabolites with systemic catecholamine metabolism. Food Funct.
2017, 8, 4570–4581. [CrossRef] [PubMed]
86. Zamora-Ros, R.; Rabassa, M.; Cherubini, A.; Urpi-Sarda, M.; Bandinelli, S.; Ferrucci, L.; Andres-Lacueva, C.
High concentrations of a urinary biomarker of polyphenol intake are associated with decreased mortality in
older adults. J. Nutr. 2013, 143, 1445–1450. [CrossRef]
87. Lu, L.J.; Anderson, K.E. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in
humans. Am. J. Clin. Nutr. 1998, 68, 1500S–1504S. [CrossRef]
88. Abelson, B.; Sun, D.; Que, L.; Nebel, R.A.; Baker, D.; Popiel, P.; Amundsen, C.L.; Chai, T.; Close, C.;
DiSanto, M.; et al. Sex differences in lower urinary tract biology and physiology. Biol. Sex Differ. 2018, 9, 45.
[CrossRef]
89. Adlercreutz, H.; Pulkkinen, M.O.; Hamalainen, E.K.; Korpela, J.T. Studies on the role of intestinal bacteria in
metabolism of synthetic and natural steroid hormones. J. Steroid Biochem. 1984, 20, 217–229. [CrossRef]
90. Wu, P.; Chen, Y.; Zhao, J.; Zhang, G.; Chen, J.; Wang, J.; Zhang, H. Urinary microbiome and psychological
factors in women with overactive bladder. Front. Cell. Infect. Microbiol. 2017, 7, 488. [CrossRef]
91. Albert, P.R. Why is depression more prevalent in women? J. Psychiatry Neurosci. 2015, 40, 219–221. [CrossRef]
Nutrients 2019, 11, 1637 20 of 25
92. Li, H.; He, J.; Jia, W. The influence of gut microbiota on drug metabolism and toxicity. Expert Opin. Drug
Metab. Toxicol. 2016, 12, 31–40. [CrossRef]
93. Edogawa, S.; Peters, S.A.; Jenkins, G.D.; Gurunathan, S.V.; Sundt, W.J.; Johnson, S.; Lennon, R.J.; Dyer, R.B.;
Camilleri, M.; Kashyap, P.C.; et al. Sex differences in NSAID-induced perturbation of human intestinal
barrier function and microbiota. FASEB J. 2018, 32, 6615–6625. [CrossRef]
94. Haro, C.; Rangel-Zuniga, O.A.; Alcala-Diaz, J.F.; Gomez-Delgado, F.; Perez-Martinez, P.; Delgado-Lista, J.;
Quintana-Navarro, G.M.; Landa, B.B.; Navas-Cortes, J.A.; Tena-Sempere, M.; et al. Intestinal microbiota is
influenced by gender and body mass index. PLoS ONE 2016, 11, e0154090. [CrossRef]
95. Sinha, T.; Vich Vila, A.; Garmaeva, S.; Jankipersadsing, S.A.; Imhann, F.; Collij, V.; Bonder, M.J.; Jiang, X.;
Gurry, T.; Alm, E.J.; et al. Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles.
Gut Microbes 2018, 10, 358–366. [CrossRef]
96. Santos-Marcos, J.A.; Rangel-Zuniga, O.A.; Jimenez-Lucena, R.; Quintana-Navarro, G.M.; Garcia-Carpintero, S.;
Malagon, M.M.; Landa, B.B.; Tena-Sempere, M.; Perez-Martinez, P.; Lopez-Miranda, J.; et al. Influence of
gender and menopausal status on gut microbiota. Maturitas 2018, 116, 43–53. [CrossRef]
97. Baker, J.M.; Al-Nakkash, L.; Herbst-Kralovetz, M.M. Estrogen-gut microbiome axis: Physiological and
clinical implications. Maturitas 2017, 103, 45–53. [CrossRef]
98. Pollet, R.M.; D’Agostino, E.H.; Walton, W.G.; Xu, Y.; Little, M.S.; Biernat, K.A.; Pellock, S.J.; Patterson, L.M.;
Creekmore, B.C.; Isenberg, H.N.; et al. An atlas of beta-Glucuronidases in the human intestinal microbiome.
Structure 2017, 25, 967–977. [CrossRef]
99. Ridlon, J.M.; Ikegawa, S.; Alves, J.M.; Zhou, B.; Kobayashi, A.; Iida, T.; Mitamura, K.; Tanabe, G.; Serrano, M.;
De Guzman, A.; et al. Clostridium scindens: A human gut microbe with a high potential to convert glucocorticoids
into androgens. J. Lipid Res. 2013, 54, 2437–2449. [CrossRef]
100. Wankhade, U.D.; Zhong, Y.; Lazarenko, O.P.; Chintapalli, S.V.; Piccolo, B.D.; Chen, J.R.; Shankar, K. Sex-specific
changes in gut microbiome composition following blueberry consumption in C57BL/6J mice. Nutrients 2019,
11, 313. [CrossRef]
101. Barrea, L.; Annunziata, G.; Muscogiuri, G.; Laudisio, D.; Di Somma, C.; Maisto, M.; Tenore, G.C.; Colao, A.;
Savastano, S. Trimethylamine N-oxide, Mediterranean diet, and nutrition in healthy, normal-weight adults:
Also a matter of sex? Nutrition 2018, 62, 7–17. [CrossRef]
102. Coecke, S.; Debast, G.; Phillips, I.R.; Vercruysse, A.; Shephard, E.A.; Rogiers, V. Hormonal regulation of
microsomal flavin-containing monooxygenase activity by sex steroids and growth hormone in co-cultured
adult male rat hepatocytes. Biochem. Pharmacol. 1998, 56, 1047–1051. [CrossRef]
103. Ayesh, R.; Mitchell, S.C.; Smith, R.L. Dysfunctional N-oxidation of trimethylamine and the influence of
testosterone treatment in man. Pharmacogenetics 1995, 5, 244–246. [CrossRef]
104. Neuman, H.; Koren, O. The pregnancy microbiome. Nestle Nutr. Inst. Workshop Ser. 2017, 88, 1–9.
105. Asher, G.N.; Corbett, A.H.; Hawke, R.L. Common herbal dietary supplement-drug interactions.
Am. Fam. Physician 2017, 96, 101–107.
106. Mensink, G.B.; Fletcher, R.; Gurinovic, M.; Huybrechts, I.; Lafay, L.; Serra-Majem, L.; Szponar, L.; Tetens, I.;
Verkaik-Kloosterman, J.; Baka, A.; et al. Mapping low intake of micronutrients across Europe. Br. J. Nutr.
2013, 110, 755–773. [CrossRef]
107. Eurostat. Women Use Medicine More Often Than Men European Commision. Available online: https:
//ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20170505-1?inheritRedirect=true& (accessed on
15 April 2014).
108. Levy, I.; Attias, S.; Ben-Arye, E.; Goldstein, L.; Schiff, E. Potential drug interactions with dietary and herbal
supplements during hospitalization. Intern. Emerg. Med. 2017, 12, 301–310. [CrossRef]
109. Rowland, A.; Miners, J.O.; Mackenzie, P.I. The UDP-glucuronosyltransferases: Their role in drug metabolism
and detoxification. Int. J. Biochem. Cell Biol. 2013, 45, 1121–1132. [CrossRef]
110. Murphy, P.A.; Kern, S.E.; Stanczyk, F.Z.; Westhoff, C.L. Interaction of St. John’s Wort with oral contraceptives:
Effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough
bleeding. Contraception 2005, 71, 402–408. [CrossRef]
111. Herb Research Foundation. St. John’s Wort Banned in France. Available online: http://www.herbs.org/
current/sjwfrance.htm (accessed on 29 September 2015).
112. Borrelli, F.; Izzo, A.A. Herb-drug interactions with St John’s wort (Hypericum perforatum): An update on
clinical observations. AAPS J. 2009, 11, 710–727. [CrossRef]
Nutrients 2019, 11, 1637 21 of 25
113. De Lima Toccafondo Vieira, M.; Huang, S.M. Botanical-drug interactions: A scientific perspective. Planta Med.
2012, 78, 1400–1415. [CrossRef]
114. Ostertag, L.M.; Kroon, P.A.; Wood, S.; Horgan, G.W.; Cienfuegos-Jovellanos, E.; Saha, S.; Duthie, G.G.;
de Roos, B. Flavan-3-ol-enriched dark chocolate and white chocolate improve acute measures of platelet
function in a gender-specific way–a randomized-controlled human intervention trial. Mol. Nutr. Food Res.
2013, 57, 191–202. [CrossRef]
115. Dearden, L.; Bouret, S.G.; Ozanne, S.E. Sex and gender differences in developmental programming of
metabolism. Mol. Metab. 2018, 15, 8–19. [CrossRef]
116. Saunders, E.J.; Saunders, J.A. Drug therapy in pregnancy: The lessons of diethylstilbestrol, thalidomide, and
bendectin. Health Care Women Int. 1990, 11, 423–432. [CrossRef]
117. Forster, D.A.; Denning, A.; Wills, G.; Bolger, M.; McCarthy, E. Herbal medicine use during pregnancy in a
group of Australian women. BMC Pregnancy Childbirth 2006, 6, 21. [CrossRef]
118. Bishop, J.L.; Northstone, K.; Green, J.R.; Thompson, E.A. The use of complementary and alternative medicine in
pregnancy: Data from the Avon Longitudinal Study of Parents and Children (ALSPAC). Complement. Ther. Med.
2011, 19, 303–310. [CrossRef]
119. Cuzzolin, L.; Francini-Pesenti, F.; Verlato, G.; Joppi, M.; Baldelli, P.; Benoni, G. Use of herbal products among
392 Italian pregnant women: Focus on pregnancy outcome. Pharmacoepidemiol. Drug Saf. 2010, 19, 1151–1158.
[CrossRef]
120. Kennedy, D.A.; Lupattelli, A.; Koren, G.; Nordeng, H. Herbal medicine use in pregnancy: Results of a
multinational study. BMC Complement. Altern. Med. 2013, 13, 355. [CrossRef]
121. Volqvartz, T.; Vestergaard, A.L.; Aagaard, S.K.; Andreasen, M.F.; Lesnikova, I.; Uldbjerg, N.; Larsen, A.; Bor, P.
Use of alternative medicine, ginger and licorice among Danish pregnant women—A prospective cohort
study. BMC Complement. Altern. Med. 2019, 19, 5. [CrossRef]
122. Louik, C.; Gardiner, P.; Kelley, K.; Mitchell, A.A. Use of herbal treatments in pregnancy. Am. J. Obstet. Gynecol.
2010, 202, 439.e1–439.e10. [CrossRef]
123. Yimam, M.; Lee, Y.C.; Hyun, E.J.; Jia, Q. Reproductive and developmental toxicity of orally administered
botanical composition, UP446-Part I: Effects on embryo-fetal development in New Zealand White rabbits
and Sprague Dawley rats. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2015, 104, 141–152. [CrossRef]
124. McLay, J.S.; Izzati, N.; Pallivalapila, A.R.; Shetty, A.; Pande, B.; Rore, C.; Al Hail, M.; Stewart, D. Pregnancy,
prescription medicines and the potential risk of herb-drug interactions: A cross-sectional survey. BMC Complement.
Altern. Med. 2017, 17, 543. [CrossRef]
125. Pariente, G.; Leibson, T.; Carls, A.; Adams-Webber, T.; Ito, S.; Koren, G. Pregnancy-associated changes in
pharmacokinetics: A systematic review. PLoS Med. 2016, 13, e1002160. [CrossRef]
126. Todaka, E.; Sakurai, K.; Fukata, H.; Miyagawa, H.; Uzuki, M.; Omori, M.; Osada, H.; Ikezuki, Y.; Tsutsumi, O.;
Iguchi, T.; et al. Fetal exposure to phytoestrogens–the difference in phytoestrogen status between mother
and fetus. Environ. Res. 2005, 99, 195–203. [CrossRef]
127. Bourque, S.L.; Dolinsky, V.W.; Dyck, J.R.; Davidge, S.T. Maternal resveratrol treatment during pregnancy
improves adverse fetal outcomes in a rat model of severe hypoxia. Placenta 2012, 33, 449–452. [CrossRef]
128. Jarrell, J.; Foster, W.G.; Kinniburgh, D.W. Phytoestrogens in human pregnancy. Obstet. Gynecol. Int. 2012,
2012, 850313. [CrossRef]
129. North, K.; Golding, J. A maternal vegetarian diet in pregnancy is associated with hypospadias. The ALSPAC
Study Team. Avon Longitudinal Study of Pregnancy and Childhood. BJU Int. 2000, 85, 107–113. [CrossRef]
130. Jacobsen, B.K.; Jaceldo-Siegl, K.; Knutsen, S.F.; Fan, J.; Oda, K.; Fraser, G.E. Soy isoflavone intake and the
likelihood of ever becoming a mother: The Adventist Health Study-2. Int. J. Womens Health 2014, 6, 377–384.
[CrossRef]
131. Vanegas, J.C.; Afeiche, M.C.; Gaskins, A.J.; Minguez-Alarcon, L.; Williams, P.L.; Wright, D.L.; Toth, T.L.;
Hauser, R.; Chavarro, J.E. Soy food intake and treatment outcomes of women undergoing assisted reproductive
technology. Fertil. Steril. 2015, 103, 749–755. [CrossRef]
132. Kim, J.; Kim, S.; Huh, K.; Kim, Y.; Joung, H.; Park, M. High serum isoflavone concentrations are associated
with the risk of precocious puberty in Korean girls. Clin. Endocrinol. 2011, 75, 831–835. [CrossRef]
133. Samavati, R.; Ducza, E.; Hajagos-Toth, J.; Gaspar, R. Herbal laxatives and antiemetics in pregnancy.
Reprod. Toxicol. 2017, 72, 153–158. [CrossRef]
Nutrients 2019, 11, 1637 22 of 25
134. Ouzir, M.; El Bairi, K.; Amzazi, S. Toxicological properties of fenugreek (Trigonella foenum graecum).
Food Chem. Toxicol. 2016, 96, 145–154. [CrossRef]
135. Kolding, L.; Pedersen, L.H.; Henriksen, T.B.; Olsen, J.; Grzeskowiak, L.E. Hypericum perforatum use during
pregnancy and pregnancy outcome. Reprod. Toxicol. 2015, 58, 234–237. [CrossRef]
136. Raikkonen, K.; Pesonen, A.K.; Heinonen, K.; Lahti, J.; Komsi, N.; Eriksson, J.G.; Seckl, J.R.; Jarvenpaa, A.L.;
Strandberg, T.E. Maternal licorice consumption and detrimental cognitive and psychiatric outcomes in
children. Am. J. Epidemiol. 2009, 170, 1137–1146. [CrossRef]
137. Strandberg, T.E.; Jarvenpaa, A.L.; Vanhanen, H.; McKeigue, P.M. Birth outcome in relation to licorice
consumption during pregnancy. Am. J. Epidemiol. 2001, 153, 1085–1088. [CrossRef]
138. Nazari, S.; Rameshrad, M.; Hosseinzadeh, H. Toxicological effects of Glycyrrhiza glabra (Licorice): A review.
Phytother. Res. 2017, 31, 1635–1650. [CrossRef]
139. Qiu, J.X.; Zhou, Z.W.; He, Z.X.; Zhang, X.; Zhou, S.F.; Zhu, S. Estimation of the binding modes with important
human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger
components using molecular docking, computational, and pharmacokinetic modeling studies. Drug Des.
Devel. Ther. 2015, 9, 841–866.
140. Banihani, S.A. Ginger and testosterone. Biomolecules 2018, 8, 119. [CrossRef]
141. Sondergaard, K. Ginger, pregnancy nausea and possible fetal injuries (testosterone effect). Ugeskr. Laeger
2008, 170, 359.
142. Marx, W.; McKavanagh, D.; McCarthy, A.L.; Bird, R.; Ried, K.; Chan, A.; Isenring, L. The effect of Ginger
(Zingiber officinale) on platelet aggregation: A systematic literature review. PLoS ONE 2015, 10, e0141119.
143. Gonzalez-Nahm, S.; Mendez, M.; Robinson, W.; Murphy, S.K.; Hoyo, C.; Hogan, V.; Rowley, D. Low maternal
adherence to a Mediterranean diet is associated with increase in methylation at the MEG3-IG differentially
methylated region in female infants. Environ. Epigenet. 2017, 3, dvx007. [CrossRef]
144. Malireddy, S.; Kotha, S.R.; Secor, J.D.; Gurney, T.O.; Abbott, J.L.; Maulik, G.; Maddipati, K.R.; Parinandi, N.L.
Phytochemical antioxidants modulate mammalian cellular epigenome: Implications in health and disease.
Antioxid. Redox Signal. 2012, 17, 327–339. [CrossRef]
145. Facchinetti, F.; Pedrielli, G.; Benoni, G.; Joppi, M.; Verlato, G.; Dante, G.; Balduzzi, S.; Cuzzolin, L. Herbal
supplements in pregnancy: Unexpected results from a multicentre study. Hum. Reprod. 2012, 27, 3161–3167.
[CrossRef]
146. Budzynska, K.; Gardner, Z.E.; Dugoua, J.J.; Low Dog, T.; Gardiner, P. Systematic review of breastfeeding and
herbs. Breastfeed. Med. 2012, 7, 489–503. [CrossRef]
147. Sim, T.F.; Sherriff, J.; Hattingh, H.L.; Parsons, R.; Tee, L.B. The use of herbal medicines during breastfeeding:
A population-based survey in Western Australia. BMC Complement. Altern. Med. 2013, 13, 317. [CrossRef]
148. Zuppa, A.A.; Sindico, P.; Orchi, C.; Carducci, C.; Cardiello, V.; Romagnoli, C. Safety and efficacy of
galactogogues: Substances that induce, maintain and increase breast milk production. J. Pharm. Pharm. Sci.
2010, 13, 162–174. [CrossRef]
149. Zapantis, A.; Steinberg, J.G.; Schilit, L. Use of herbals as galactagogues. J. Pharm. Pract. 2012, 25, 222–231.
[CrossRef]
150. Bazzano, A.N.; Cenac, L.; Brandt, A.J.; Barnett, J.; Thibeau, S.; Theall, K.P. Maternal experiences with and
sources of information on galactagogues to support lactation: A cross-sectional study. Int. J. Womens Health
2017, 9, 105–113. [CrossRef]
151. Sahin, B.; Kaymaz, N.; Yildirim, S. Herbal remedies for perceived inadequate milk supply are perhaps not as
safe as women think: A brief case report. Women Birth 2016, 29, e133. [CrossRef]
152. National Institute of Health. Goat’s Rue; U.S. National Library of Medicine: Washington, DC, USA, 2018.
153. Galante, L.; Milan, A.M.; Reynolds, C.M.; Cameron-Smith, D.; Vickers, M.H.; Pundir, S. Sex-specific human milk
composition: The role of infant sex in determining early life nutrition. Nutrients 2018, 10, 1194. [CrossRef]
154. Powe, C.E.; Knott, C.D.; Conklin-Brittain, N. Infant sex predicts breast milk energy content. Am. J. Hum. Biol.
2010, 22, 50–54. [CrossRef]
155. Fujita, M.; Roth, E.; Lo, Y.J.; Hurst, C.; Vollner, J.; Kendell, A. In poor families, mothers’ milk is richer for
daughters than sons: A test of Trivers-Willard hypothesis in agropastoral settlements in Northern Kenya.
Am. J. Phys. Anthropol. 2012, 149, 52–59. [CrossRef]
Nutrients 2019, 11, 1637 23 of 25
156. Romaszko, E.; Wiczkowski, W.; Romaszko, J.; Honke, J.; Piskula, M.K. Exposure of breastfed infants to
quercetin after consumption of a single meal rich in quercetin by their mothers. Mol. Nutr. Food Res. 2014, 58,
221–228. [CrossRef]
157. Patisaul, H.B. Endocrine disruption by dietary phyto-oestrogens: Impact on dimorphic sexual systems and
behaviours. Proc. Nutr. Soc. 2017, 76, 130–144. [CrossRef]
158. Jonker, J.W.; Merino, G.; Musters, S.; van Herwaarden, A.E.; Bolscher, E.; Wagenaar, E.; Mesman, E.; Dale, T.C.;
Schinkel, A.H. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic
xenotoxins into milk. Nat. Med. 2005, 11, 127–129. [CrossRef]
159. Tamaki, H.; Satoh, H.; Hori, S.; Ohtani, H.; Sawada, Y. Inhibitory effects of herbal extracts on breast cancer resistance
protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab. Pharmacokinet. 2010, 25,
170–179. [CrossRef]
160. Moossavi, S.; Sepehri, S.; Robertson, B.; Bode, L.; Goruk, S.; Field, C.J.; Lix, L.M.; de Souza, R.J.; Becker, A.B.;
Mandhane, P.J.; et al. Composition and variation of the human milk microbiota are influenced by maternal
and early-life factors. Cell Host Microbe 2019, 25, 324–335. [CrossRef]
161. Urbaniak, C.; Angelini, M.; Gloor, G.B.; Reid, G. Human milk microbiota profiles in relation to birthing
method, gestation and infant gender. Microbiome 2016, 4, 1. [CrossRef]
162. Baumann-Dudenhoeffer, A.M.; D’Souza, A.W.; Tarr, P.I.; Warner, B.B.; Dantas, G. Infant diet and maternal
gestational weight gain predict early metabolic maturation of gut microbiomes. Nat. Med. 2018, 24, 1822–1829.
[CrossRef]
163. Fernandez, L.; Ruiz, L.; Jara, J.; Orgaz, B.; Rodriguez, J.M. Strategies for the preservation, restoration and
modulation of the human milk microbiota. Implications for human milk banks and neonatal intensive care
units. Front. Microbiol. 2018, 9, 2676. [CrossRef]
164. National Toxicology Program; National Institute of Environmental Health Science. Draft NTP Brief on
Soy Infant Formula; National Institutes of Health, Ed.; U.S. Department of Health and Human Services:
Washington, DC, USA, 2010.
165. Adgent, M.A.; Daniels, J.L.; Rogan, W.J.; Adair, L.; Edwards, L.J.; Westreich, D.; Maisonet, M.; Marcus, M.
Early-life soy exposure and age at menarche. Paediatr. Perinat. Epidemiol. 2012, 26, 163–175. [CrossRef]
166. D’Aloisio, A.A.; DeRoo, L.A.; Baird, D.D.; Weinberg, C.R.; Sandler, D.P. Prenatal and infant exposures and
age at menarche. Epidemiology 2013, 24, 277–284. [CrossRef]
167. D’Aloisio, A.A.; Baird, D.D.; DeRoo, L.A.; Sandler, D.P. Early-life exposures and early-onset uterine
leiomyomata in black women in the Sister Study. Environ. Health Perspect. 2012, 120, 406–412. [CrossRef]
168. Upson, K.; Sathyanarayana, S.; Scholes, D.; Holt, V.L. Early-life factors and endometriosis risk. Fertil. Steril.
2015, 104, 964–971. [CrossRef]
169. Newbold, R.R.; Banks, E.P.; Bullock, B.; Jefferson, W.N. Uterine adenocarcinoma in mice treated neonatally
with Genistein. Cancer Res. 2001, 61, 4325–4328.
170. McCarver, G.; Bhatia, J.; Chambers, C.; Clarke, R.; Etzel, R.; Foster, W.; Hoyer, P.; Leeder, J.S.; Peters, J.M.;
Rissman, E.; et al. NTP-CERHR expert panel report on the developmental toxicity of soy infant formula.
Birth Defects Res. Part B Dev. Reprod. Toxicol. 2011, 92, 421–468. [CrossRef]
171. Setchell, K.D.; Zimmer-Nechemias, L.; Cai, J.; Heubi, J.E. Exposure of infants to phyto-oestrogens from
soy-based infant formula. Lancet 1997, 350, 23–27. [CrossRef]
172. Irvine, C.H.; Fitzpatrick, M.G.; Alexander, S.L. Phytoestrogens in soy-based infant foods: Concentrations,
daily intake, and possible biological effects. Proc. Soc. Exp. Biol. Med. 1998, 217, 247–253. [CrossRef]
173. Cao, Y.; Calafat, A.M.; Doerge, D.R.; Umbach, D.M.; Bernbaum, J.C.; Twaddle, N.C.; Ye, X.; Rogan, W.J.
Isoflavones in urine, saliva, and blood of infants: Data from a pilot study on the estrogenic activity of soy
formula. J. Expo. Sci. Environ. Epidemiol. 2009, 19, 223–234. [CrossRef]
174. Koleva, P.T.; Tun, H.M.; Konya, T.; Guttman, D.S.; Becker, A.B.; Mandhane, P.J.; Turvey, S.E.; Subbarao, P.;
Sears, M.R.; Scott, J.A.; et al. Sex-specific impact of asthma during pregnancy on infant gut microbiota.
Eur. Respir. J. 2017, 50, 1700280. [CrossRef]
175. Harding, J.E.; Cormack, B.E.; Alexander, T.; Alsweiler, J.M.; Bloomfield, F.H. Advances in nutrition of the
newborn infant. Lancet 2017, 389, 1660–1668. [CrossRef]
176. Roseboom, T.J.; Painter, R.C.; van Abeelen, A.F.; Veenendaal, M.V.; de Rooij, S.R. Hungry in the womb: What
are the consequences? Lessons from the Dutch famine. Maturitas 2011, 70, 141–145. [CrossRef]
Nutrients 2019, 11, 1637 24 of 25
177. Griffin, R.M.; Hayward, A.D.; Bolund, E.; Maklakov, A.A.; Lummaa, V. Sex differences in adult mortality rate
mediated by early-life environmental conditions. Ecol. Lett. 2018, 21, 235–242. [CrossRef]
178. Broere-Brown, Z.A.; Baan, E.; Schalekamp-Timmermans, S.; Verburg, B.O.; Jaddoe, V.W.; Steegers, E.A.
Sex-specific differences in fetal and infant growth patterns: A prospective population-based cohort study.
Biol. Sex Differ. 2016, 7, 65. [CrossRef]
179. Brown, Z.A.; Schalekamp-Timmermans, S.; Tiemeier, H.W.; Hofman, A.; Jaddoe, V.W.; Steegers, E.A. Fetal sex
specific differences in human placentation: A prospective cohort study. Placenta 2014, 35, 359–364. [CrossRef]
180. Melamed, N.; Meizner, I.; Mashiach, R.; Wiznitzer, A.; Glezerman, M.; Yogev, Y. Fetal sex and intrauterine
growth patterns. J. Ultrasound Med. 2013, 32, 35–43. [CrossRef]
181. Ford, N.D.; Behrman, J.R.; Hoddinott, J.F.; Maluccio, J.A.; Martorell, R.; Ramirez-Zea, M.; Stein, A.D. Exposure
to improved nutrition from conception to age 2 years and adult cardiometabolic disease risk: A modelling
study. Lancet Glob. Health 2018, 6, e875–e884. [CrossRef]
182. Marks, K.J.; Hartman, T.J.; Taylor, E.V.; Rybak, M.E.; Northstone, K.; Marcus, M. Exposure to phytoestrogens
in utero and age at menarche in a contemporary British cohort. Environ. Res. 2017, 155, 287–293. [CrossRef]
183. Raikkonen, K.; Martikainen, S.; Pesonen, A.K.; Lahti, J.; Heinonen, K.; Pyhala, R.; Lahti, M.; Tuovinen, S.;
Wehkalampi, K.; Sammallahti, S.; et al. Maternal Licorice consumption during pregnancy and pubertal,
cognitive, and psychiatric outcomes in children. Am. J. Epidemiol. 2017, 185, 317–328. [CrossRef]
184. Simmler, C.; Pauli, G.F.; Chen, S.N. Phytochemistry and biological properties of glabridin. Fitoterapia 2013,
90, 160–184. [CrossRef]
185. Jefferson, W.N.; Padilla-Banks, E.; Newbold, R.R. Adverse effects on female development and reproduction
in CD-1 mice following neonatal exposure to the phytoestrogen genistein at environmentally relevant doses.
Biol. Reprod. 2005, 73, 798–806. [CrossRef]
186. Gorski, J.C.; Huang, S.M.; Pinto, A.; Hamman, M.A.; Hilligoss, J.K.; Zaheer, N.A.; Desai, M.; Miller, M.; Hall, S.D.
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther. 2004,
75, 89–100. [CrossRef]
187. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Cui, Y.; Ang, C.Y. Cytochrome P450
phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 2002, 72, 276–287.
[CrossRef]
188. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Cui, Y.; Ang, C.Y. Clinical assessment
of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic
oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005, 22, 525–539. [CrossRef]
189. Showande, S.J.; Fakeye, T.O.; Kajula, M.; Hokkanen, J.; Tolonen, A. Potential inhibition of major human
cytochrome P450 isoenzymes by selected tropical medicinal herbs-Implication for herb-drug interactions.
Food Sci. Nutr. 2018, 7, 44–55. [CrossRef]
190. Mukherjee, P.K.; Ponnusankar, S.; Pandit, S.; Hazam, P.K.; Ahmmed, M.; Mukherjee, K. Botanicals as
medicinal food and their effects on drug metabolizing enzymes. Food Chem. Toxicol. 2011, 49, 3142–3153.
[CrossRef]
191. Satoh, T.; Fujisawa, H.; Nakamura, A.; Takahashi, N.; Watanabe, K. Inhibitory effects of eight green tea
catechins on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activities. J. Pharm. Pharm. Sci. 2016, 19, 188–197.
[CrossRef]
192. Guo, Y.; Chen, Y.; Tan, Z.R.; Klaassen, C.D.; Zhou, H.H. Repeated administration of berberine inhibits
cytochromes P450 in humans. Eur. J. Clin. Pharmacol. 2012, 68, 213–217. [CrossRef]
193. Foster, B.C.; Foster, M.S.; Vandenhoek, S.; Krantis, A.; Budzinski, J.W.; Arnason, J.T.; Gallicano, K.D.;
Choudri, S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic.
J. Pharm. Pharm. Sci. 2001, 4, 176–184.
194. Yin, O.Q.; Tomlinson, B.; Waye, M.M.; Chow, A.H.; Chow, M.S. Pharmacogenetics and herb-drug interactions:
Experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004, 14, 841–850. [CrossRef]
195. Kalsotra, A.; Anakk, S.; Boehme, C.L.; Strobel, H.W. Sexual dimorphism and tissue specificity in the expression
of CYP4F forms in Sprague Dawley rats. Drug Metab. Dispos. 2002, 30, 1022–1028. [CrossRef]
196. Gurley, B.J.; Swain, A.; Hubbard, M.A.; Williams, D.K.; Barone, G.; Hartsfield, F.; Tong, Y.; Carrier, D.J.;
Cheboyina, S.; Battu, S.K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects
of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Mol. Nutr. Food Res.
2008, 52, 755–763. [CrossRef]
Nutrients 2019, 11, 1637 25 of 25
197. Lown, K.S.; Bailey, D.G.; Fontana, R.J.; Janardan, S.K.; Adair, C.H.; Fortlage, L.A.; Brown, M.B.; Guo, W.;
Watkins, P.B. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A
protein expression. J. Clin. Investig. 1997, 99, 2545–2553. [CrossRef]
198. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Carrier, J.; Khan, I.A.; Edwards, D.J.;
Shah, A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus
aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther. 2004, 76, 428–440.
[CrossRef]
199. Hajda, J.; Rentsch, K.M.; Gubler, C.; Steinert, H.; Stieger, B.; Fattinger, K. Garlic extract induces intestinal
P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur. J. Pharm. Sci. 2010,
41, 729–735. [CrossRef]
200. Misaka, S.; Yatabe, J.; Muller, F.; Takano, K.; Kawabe, K.; Glaeser, H.; Yatabe, M.S.; Onoue, S.; Werba, J.P.;
Watanabe, H.; et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects.
Clin. Pharmacol. Ther. 2014, 95, 432–438. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
